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Abstract 
 
Infectious salmon anemia virus (ISAV) is an aquatic influensa-like virus that infects Atlantic 
salmon, causing high mortalities, and with huge economical impact in the fish farming 
industry. Outbreaks of new virulent strains is an emerging threat to the aquaculture industry 
as no appropriate vaccines to trigger the acquired immune response are yet developed. The 
interaction between the infectious agent and its host is here investigated focusing on the 
innate immune system of the Atlantic salmon (Salmo Salar) and their interactions with ISAV. 
In the host's innate response, the type 1 interferon (IFN) stands out as the first line of defence 
upon viral infection. ISAV, as other genera of Orthomyxoviridae, has evolved multiple ways 
to avoid the immediate antiviral effects of the IFN. In ISAV the segments 7ORF1 and 8ORF2 
have been shown to exert interferon antagonistic activity, but the detailed mechanisms behind 
this phenomena are yet unknown.  
In this project, the IFN antagonistic activity of ISAV has been studied. By studying the 
protein-protein interactions, the understanding of how the immune system is suppressed by 
ISAV during an ISAV infection can be increased. The effect the ISAV proteins have on the 
IFN system proteins of the signalling pathway from virus recognition to the interferon 
regulatory factors (IRFs) were analysed. This was enabled using the method of Yeast-2-
Hybrid screening for interactions and using co-immunoprecipitation for verification of the 
interactions. We found the interactions between IRF3 and the protein encoded from ISAV 
segment 8ORF2 that have similiarities with the IFN antagonistic ML-protein of Thogoviruses 
interacting with the IRF3 located in the nucleus. The other stated IFN antagonist of ISAV, 
segment 7ORF1, located in the cytoplasm was identified with interactions with IRF7a. It is 
discussed whether this interaction has features in common with the Influenza A NS segment 
that interact with IRF3 in mammals. For further verification of the protein-protein 
interactions, the ISAV segment 8ORF2 interaction with IRF3 were analysed by co-
immunoprecipitation, and a weak interaction was verified. It is discussed whether the weak 
interaction reflects the low transfection efficiency of IRF3. 
 
Keywords: Orthomyxoviruses; Infectious salmon anemia virus; ISAV; interferon antagonism; 
protein-protein interactions; virus-host interactions 
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Sammendrag 
 
Infeksiøs lakseanemi virus (ILAV) er et akvatisk influensa-lignende virus som infiserer 
Atlantisk laks og forårsaker stor dødlighet. Til nå er det ikke utviklet effektive vaksiner som 
gir god beskyttelse mot ILAV. Utbrudd av nye virulente stammer utgjør derfor en voksende 
trussel mot fiskeindustrien. Samspillet mellom smittestoffet og dens vert er i denne studien 
undersøkt med fokus på interaksjonene mellom det medfødte immunsystemet hos atlantisk 
laks (Salmo Salar) og ILAV. I vertens medfødte immunrespons utgjør type I interferon (IFN) 
et førstelinjeforsvaret ved virale infeksjoner. ILAV har som andre genera av 
Orthomyxoviridae utviklet flere måter å unnslippe den umiddelbare antivirale effekten av 
IFN. ILA virus segmentene 7ORF1 og 8ORF2 har begge IFN antagonistisk aktivitet, men de 
underliggende mekanismerne bak dette er fortsatt ukjente.  
 
I denne studien har de IFN antagonistiske aktivitetene hos ILAV blitt studert på basis av 
protein-protein interaksjoner for å øke forståelse av hvordan ILAV unnslipper vertens 
immunforsvar i løpet av en infeksjon. Vi har analysert IFN system proteiner i signalkjeden fra 
virusdeteksjon til interferon regulatoriske faktorer (IRF)s sammen med proteiner av ILAV. 
Dette ble gjort ved bruk av gjær-2-hybrid for å screene protein-protein interaksjoner, Co-
immunprecipitering ble så benyttet for å verifisere funnene. Ved screening ble det funnet 
interaksjoner mellom IRF3 og ILAV segment 8ORF2, begge proteinerne er lokalisert i 
kjernen. Om denne interaksjonen kan ha de samme funksjonene som de IFN antagonistiske 
ML protein av Thogovirus blir diskutert, begge er lokalisert i kjernen. Det ble også identifisert 
en interaksjon mellom segment 7ORF1 IRF7a. Det blir drøftet om denne interaksjonen har 
trekk til felles med den IFN antgonistiske interaksjonen NS 1 segmentet til Influensa A har 
med IRF3 i pattedyr begge proteiner er lokalisert i cytoplasma. En svak protein-protein 
interaksjon mellom ISAV segment 8ORF2 og IRF3 ble verifisert med co-immunpresipitering. 
Det blir diskutert om den svake interaksjonen reflekterer den lave transfiksjons effektivteten 
av IRF3 i vert. 
 
Nøkkelord: Orthomyxovirus; infektiøs lakseanemi virus; ILAV; interferon antagonisme; 
protein-protein interaksjoner; virus-vert-interaksjoner 
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Chapter 1. Introduction  
 
1.1 Infectious salmon anemia (ISA) 
 
Since the early 1980s the aqua culture of the Atlantic salmon (Salmo salar) has developed 
into a huge industry. In 2007 the production in Norway reached 800 000 tons and made up for 
44% of the global production (Solar, 2009) which had a value of 2.9 billion US$. Infectious 
salmon anemia (ISA) is a disease that counts as an emerging threat to the salmon farming 
industry. The disease was first confirmed 1984 in Norway and epidemic outbreaks of ISA 
increased in the late 1980s and the early 1990s (Vågsholm, et al., 1994). The mortality rate 
during an outbreak of ISA has reached 50% in marine farms (Thorud & Djupvik, 1988) and 
90% during in vitro trials (Hetland, et al., 2010). The preventive measures conducted by the 
European Commission forces the farmer to eradication of the entire fish stock and waste once 
ISA is detected, causing huge economic losses for the farmer. Clinical signs of ISA are 
anemia that arises from the infected and damaged blood cells, damages to the walls of the 
blood vessels, often in combination with pale gills and a swollen liver. During the last decade 
the disease has spread to the Faroe Islands, Scotland, Canada, USA, and recently an outbreak 
was detected in fish farms in Chile (Kibenge, et al., 2009) . Since the first epidemic outbreak 
of ISAV in Norway, the research effort has been strengthened to prevent new outbreaks.  
 
1.2 Infectious salmon anemia virus  (ISAV) 
 
Infectious salmon anemia virus (ISAV) causing infectious salmon anemia (ISA) was first 
isolated in 1995 (Dannevig, et al., 1995), and characterized to an aquatic orthomyxovirus in 
1997 (Mjaaland, et al., 1997). Orthomyxoviruses, like Influenza A (INVA), B (INVB), C 
(INVC), Thogovirus and the current studied ISA virus genera, have characteristics of 
negative-sense, single-stranded (ss) RNA and segmented RNA genome (Knipe & Howley, 
2007). The INV A, B and C have the ability to evolve their virulence through genetic 
reassortent within the segmented RNA genome (Palese, 1977) and ISAV has been shown to 
1. Introduction 
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evolve virulence through the same mechanism (Markussen, et al., 2008). The ISAV particle 
has eight genomic segments encoding for at least 10 viral proteins (Biering, et al., 2002). 
Segment one is the largest and segment eight is the smallest, see figure 1.  
 
 
Figure 1.Viral segments and their encoding viral proteins of ISAV. 
The viral segments 1,2 and 4 encode the viral polymerases PB2, PB1 and PA, respectively, while the viral 
segment 3 encode the nucleoprotein (NP). Gene segment 5 and 6 encode the surface fusion (F) protein and 
Hemagglututinin-esterase (HE) protein. The two smallest segments (segment 7 and 8) encode for two proteins 
each. 
 
1.2.1	   ISAV	  segments	  
 
To understand how the virus infection triggers the host immune response we need to look 
deeper into each virus protein and their interactions with key proteins of the salmon immune 
system.  
 
Viral Polymerases of ISAV 
The RNA dependent RNA polymerases have a merged structure of the three proteins; 
polymerase basic protein 1 (PB1), polymerase basic protein 2 (PB2), and polymerase acidic 
protein (PA). The basic polymerase PB2 introduces the cap binding sites and as with the 
1. Introduction 
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Influenza viruses all ISAV segments are capped with host “look-a like” structures. This 
enables capped viral mRNA to leave the core for translation in the cytoplasm (Snow, et al., 
2003). The basic polymerase PB1 act as a backbone complex during vRNA production (Snow 
et al., 2003), while the acid polymerase PA is most likely necessary for both replication and 
transcription of vRNA (Falk, et al., 2004). 
 
Nucleoprotein (NP) 
The Nucleoprotein (NP) of ISAV is suggested to have the same configuration in the lumen as 
Influenza viruses. That form ribonucleic-protein complexes (RNPs) through binding of the 
viral RNA (vRNA) to the viral polymerases PB2, PB1, PA and the NP (Falk, et al., 2004). 
RNPs synthesize complementary RNA (cRNA) as template for the synthesis of new vRNA. 
Finally, the nucleoprotein also has a nuclear localisation protein (NLS) transport signal 
peptide that ensures vRNA transport into the nucleus (Asphaug, et al., 2004).  
 
Fusion (F) 
The first surface protein of ISAV segment 5 is responsible for fusion of viral and cellular 
membranes (Aspehaug, et al., 2005). All enveloped virus which have multi-layered shells and 
one lipid enveloped surface needs the fusion protein to merge the viral and host cell 
membranes in order for the virus to entry the host cell where the virus replicates (Harrison, 
2005).  
 
Hemagglututinin-esterase (HE) 
Segment 6 encodes the second surface protein handling the host-cell receptor-binding and -
release activity (Aspehaug, et al., 2005). First, the virus binds to the cell surface using 
acetylated sialic acid as a receptor on the cell surface (Hellebo, et al., 2004). Second, the 
esterase properties is involved in the releases of ISAV from the cell (Aspehaug, et al., 2005). 
 
Proteins encoded from ISAV segment 7 and 8 
The two smallest ISAV fragments 7 and 8 encodes at least four proteins, where two of them 
have type-1 interferon antagonistic activity; 7ORF1 (McBeath et al., 2006) and 8ORF2 
(GarcÌa-Rosado et al., 2008). Both have been located in the host by confocal microscopy; 
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7ORF1 to the cytoplasm and the 8ORF2 to the nucleus (GarcÌa-Rosado et al., 2008). Segment 
7ORF1 encodes a non-structural protein expressed early in infection, while the 8ORF2 
segment encodes a structural protein expressed late in infection (Biering, et al., 2002). The 
ISAV 7ORF2 is a possible analogue to the INVs nuclear export proteins (NEP) that export 
RNPs from the nucleus to the cytoplasm (O'Neill, et al., 1998). Segment 8ORF1 encodes the 
matrix protein located under the lipid bilayer (Falk, et al., 2004). 
 
1.2.2	   ISAV	  replication	  cycle	  
The ISAV replication cycle is initiated by binding of the HE protein to acetylated sialic acid 
specific receptors on the cell surface, which triggers a receptor mediated endocytosis (Knipe 
& Howeley, 2007). The adsorption of ISAV to the cell surface results in inward budding of 
the plasma membrane of the cell and low pH in the endocytic compartments triggers fusion of 
the viral and endosome membranes. Resulting in the uncoating of ISAV and release of vRNA 
into the cytoplasm (Skehel & Wiley, 2000). The NLS in the nucleoprotein then ensures the 
transport of vRNA into the nucleus (Asphaug, et al., 2004) where the virus segments uses the 
cells own expression machinery. The viral genome (vRNA) is replicated from vRNA through 
complementary RNA (cRNA) to get positive-sense translating mRNA. In other words vRNA 
is the template for both mRNA and cRNA (Knipe & Howley, 2007). Early translated viral 
proteins necessary for secondary mRNA transcription, cRNA- and vRNA synthesis are 
translated in the cytoplasm and re-imported as proteins to the nucleus, as illustrated in figure 
2. 
 
Synthesised vRNPs and viral mRNA are exported from the nucleus by the nuclear export 
proteins (NEP) to the cytoplasm. The viral mRNA is translated in the cytoplasm and the 
posttranslational processing of HE and F proteins delivers these viral membrane proteins on 
the surface of the host cell. The M proteins along with the eight vRNPs assemble close to the 
HE and F coated plasma membrane, where the RNA genome is packed and buds off, coated 
with the lipid membrane derived from the host cell, see figure 2. The M protein, mediates the 
budding of a new ISAV particle, and the closure of buds and the virion release is mediated by 
the esterase of the HE-esterase (Aspehaug, et al., 2005). The whole replication cycle is 
illustrated in figure 2. 
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Figure 2. Illustration of the Influenza virus replication (Knipe, 2007). 
 
 
1.3 The Viral defence of Atlantic salmon  
 
A virus is an infectious, intracellular parasitic particle dependent on the host cell to implement 
replication. The host’s first line of defence against viral infection is the innate immunity that 
acts rapidly with minor specificity but putting the viral genome under strong selection 
pressure forcing evolutionary adaptation for viral replication. After the first line of defence 
the innate response precedes the acquired immunity that act after several days or weeks 
(Samuel, 2001 ) with high specificity and often provides lifelong immunity. However, the 
Atlantic salmon lacks bone marrow and defined lymphoid tissue. Instead, the head kidney 
serves as major lymphoid organ in addition to the thymus and spleen (Press & Evensen,1999). 
Many of the proteins involved in the salmon immunity have recently been characterized with 
the same properties as for mammals. The cytokine interferon has also been characterized in 
Atlantic salmon (Kileng, et al, 2009). In fact the interferon has a highly central role in the 
innate immune response upon viral infection (Garcia-Sastre & Biron, 2006).  
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Interferon Type I system 
 
The Interferon (IFN) was discovered by Isacs and Lindenmann (1957) and described as an 
agent that inhibited the replication of influenza virus. IFN is today used therapeutically in 
treatment of some viral diseases (Borden, et al., 2007). Type I IFNs include IFN α/β secreted 
by the leucocytes in the Atlantic salmon and induces antiviral defences in neighbouring cells, 
protecting them from becoming infected (Berg, et al., 2009). IFN α/β are transcriptionally 
activated by viral infection (Robertsen, 2006), (figure 3.). The secretion of IFNs acts quickly 
after viral entry as a “first line of defence” immune response that stimulates or informs the 
recipient cells through the IFN receptor (IFNR). The trans membriane IFNR precedes a 
signalling cascade via the Jak-STAT pathway, illustrated in figure 3.  
 
Figure 3. A simplified model of the type 1 Interferon system (IFN-system), illustrating the viral induction of IFN 
after viral recognition of the cell pattern recognition receptors (PRR). Recognition of ISAV in the endoplasm 
activates IRF3 by phosphorylation. IRF3 mediates to the nucleus together with Nf-kB and binds the IFN 
promoter that activates IFN production. The secreted IFN informs neighbouring cells in the form of a sos-signal 
that activates antiviral protein providing an antiviral state in the cell, in addition to further IFN production. 
 
Jak kinases activate STAT1 and STAT2 through phosphorylation (Garcia-Sastre & Biron, 
2006). The activation of STAT1 and STAT2 subsequently trigger a large number of IFN-
stimulated genes (ISGs) (Robertsen, 2006). Which results in the production of antiviral 
proteins that protects surrounding cells from viral infection. There are several well studied 
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antiviral proteins for mammals (Katze, et al., 2002 ), while the myxovirus resistance proteins 
(Mx)  and IFN-induced stimulated gene (ISG) 15 are known antiviral protein identified in the 
Atlantic salmon genome (Robertsen, 2011).  
 
The IFN-γ from type II IFN is also shown in Atlantic salmon (Kileng, et al., 2009) that 
increases the ability of the major histocompatibility complex (MHC) class I to present the 
antigen to T cells in the acquired immune response (Robertsen, 2006). Moreover, IFN-γ 
secreted by macrophages or dendritic cells activates the acquired immune system in the 
maturation of dendritic cells and activation of natural killer cells (Stetson & Medzhitov, 
2006). This indicates that IFNs has a crucial role in regulating innate immune responses, and 
also have factors in the acquired immunity. 
 
1.3.1	   The	  acquired	   immune	   response	   in	  Atlantic	   salmon	  upon	  viral	   infection	   and	  
vaccination	  
 
As the name suggests the adaptive immune system is not active at birth but has to be 
stimulated by antigens to develop. Former antigen structures or virus fragments from vaccines 
are memorized by the acquired immune system to facilitate the elimination of the antigen 
upon a re-infection. The acquired immune system in Atlantic salmon is thought to be well 
developed and as the MHC class I and II was localized (Grimholt et al., 2003). Upon viral 
infection the acquired immune response includes lymphocytes, B cells and T cells in addition 
to a cascade of other cells. Antigen stimulated B cells becomes mature B cells. These mature 
B-cells have metabolized an antigen and present fragments of the antigen at the cell surface. 
Furthermore, B-cells produce memory cells involving the cell-mediated immunity or become 
a plasma cell, both essential elements of the humoral immunity. Intracellular pathogens as 
virus are often regulated by the cell-mediated immunity rely on the MHC I molecule. The 
MHC I molecule sits on the surface of all nucleated cells and present antigens to a matching 
T-cell and their T-cell receptors (TCR). MHC I involves the cytosolic pathway that 
comprehends the intracellular immune response against virus. The cytosolic pathway activate 
T helper (TH1) involved in the cellular response stimulating production of memory cells 
(William, 2008).  
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1.4 Recognition of viral RNA and signalling pathways      
 
The ISAV entries the host cell through receptor-mediated endocytosis. This is followed by the 
fusion of the virus membrane and the endosome membrane, resulting in release of ISAV in 
the endosome compartment. PRRs distinguishes viral ssRNA from other nucleic acids or 
nucleic acid fragments that are not normally found in the endosome (Haller, et al., 2006). 
Toll-like receptors are PRRs that recognize viral single and double stranded RNA as well as 
DNA. The Toll-like receptors; TLR 3, TLR 7 and TLR 8 are all important for viral 
recognition in the endosome compartments, see table 1. TLRs have a trans membrane part 
through the endosome membrane and a cytoplasmic part in the cytoplasm, see figure 4.  
 
Table 1. Recognition of foreign nucleic acids by PRRs 
Location PRRs    Viral nucleic acids   
Endosome  TLR3    dsRNA     
Endosome  TLR7/8    ssRNA     
Endosome  TLR9    DNA   
  
 
As illustrated in Figure 4, Toll-like receptors activate the IFN system through specific 
signalling pathways to induce the gene expression of antiviral proteins.  
 
The IFN system regulation in mammals is initiated by TLR 7/8 and TLR 9 both inducing the 
Interferon type 1 response by a signalling pathway through MyD88 (figure 4.), referred to as 
the “MyD88 dependent pathway” (Hacker, et al., 2006). Another point of view is that MyD88 
primary induces the interleukin expression (Leichtle, et al., 2009 ). The TLR3 on the other 
hand strictly signals through the TriF adaptor molecule to induce type I interferon (IFN) 
expression and has recently been found to recognize ssRNA from Influenza A virus (Le 
Goffic, et al., 2006). Furthermore, IRF7 is thought to help IRF3 in the IFN production 
(Honda & Shimada, 2005). Moreover, the induction of IFN triggers transcription of IRF7A 
that enhance the production of IFN in a positive feedback loop, suggesting that even small 
viral stimuli are sufficient for a strong activation of the IFN-signalling (Haller, et al., 2006). 
The IRF3 and IRF7 are even thought to be activated in the same way (Iwamura, et al., 2001).   
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Figure 4. The recognition of viral nucleic acids by TLRs, and the TLR signalling pathways through adaptor 
molecules. TLR3 specifically signal through TriF while TLR7/8 and TLR9 signal through MyD88 as adaptor 
molecules for further signalling of antiviral response. 
 
 
1.5 Other Orthomyxoviruses with IFN-antagonistic genes 
The IFN system of the host cells that produce and secrete IFN upon the recognition of viral 
nucleic acids, play a crucial role in innate immune responses against virus infections in 
vertebrates (Haller, et al., 2007). To counteract the host defence, the ISAV segment 7ORF1 & 
8ORF2 like other orthomyxoviruses have developed IFN antagonistic activity, an unknown 
mechanism that allows the virus to escape the hosts immune response (GarcÌa-Rosado et al., 
2008). The equivalent IFN suppressor of the Influenza viruses’ is the non-structural 1 (NS1) 
protein that also counters the establishment of the IFN antiviral state. The mechanisms behind 
the NS1 suppression of IFN are not clear but the RNA-binding of NS1 is though to have an 
essential role inhibiting IRF3 (Talon, et al., 2000). The ML-protein of the Thogoviruses is 
also hypothesized as an IFN antagonistic protein (Hagmaier, et al., 2003) and demonstrated to 
inhibit virus-induced activation of IRF3, but different from that of NS1 (Jennings, et al., 
2005). Furthermore, characteristics of ML are distinct from the NS1, because ML is a 
structural protein.  
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1.6 Coiled-coil interactions 
 
A motif found regarding IFN antagonistic activity was a Coiled-coil located in the C-terminal 
of the ISAV 8ORF2 segment (GarcÌa-Rosado et al., 2008). No structural studies have shown 
the folding of the ISAV 8ORF2, but coiled-coils are known to form in dimeric structures 
(Qin, et al., 2003). Other protein interactions that were investigated in this master project 
were the previously characterized IRF3s of the Atlantic salmon (Bergan, et al., 2010). For 
mammals, the C-terminal dimerization of IRF3 is responsible translocation in to the cell core 
and binding of the IFN promoter, see figure 5. Yet, less is known about the interactions where 
the IRF3 of the Atlantic salmon is involved. 
 
 
 
Figure 5. Illustration of the structure of IRF3 that is activated by phosphorylation. In the C-terminal a dimer 
structure is formed, assured to be essential for the N-terminal DNA binding domain to bind the IFN promoter 
(Dragan, 2007). 
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The IRF3 involved in the IFN system is activated upon virus infection by phosphorylations in 
the C-terminal transactivation domain (CTD). Phosphorylated IRF3 translocate to the nucleus 
where the coiled coil motifs of CTD provides dimerization and enables IRF3 to bind the IFN 
promoter as a dimmer (Dragan, et al., 2007). The totally negative charge of the non-activated 
IRF3 seems to be an important difference between this and the activated IRF3, as illustrated 
in figure 6. 
 
 
 
Figure 6a. Illustration of the binding of monomeric wild type (WT) IRF3 to the PRDI and PRDIII sites of the 
IFN promoter. Figure 6b. Binding of the phosphorylated, i.e. activated dimericIRF3 to the PRDI and PRDIII 
sites of the IFN-B promoter (Dragan, et al., 2007). 
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1.7  Aim of study 
 
A long-term goal of this project is to provide detailed understanding of the mechanisms that 
enables ISAV to replicate in the Atlantic salmon cell. To do this the ISAV interactions with 
the host´s antiviral immune defence was studied. This is important in order to develop new 
methods for preventing and controlling ISAV that causes an emerging threat to the Atlantic 
salmon farming industry, as the present preventations like ISAV vaccines are not efficient 
enough.  
 
In this thesis the main objectives was to explore protein-protein interactions committed 
between the ISAV and the interferon system of Atlantic salmon. This was achieved using 
Yeast-two-hybrid (Y2H) screening for interactions and co-immunoprecipitation (co-IP) for 
verification of the Y2H findings. 
 
The work included the following tasks: 
   
• Investigate protein-protein interactions between the ISAV proteins 
• Study protein interactions between key proteins of the Atlantic salmon interferon type 
I system and the ISAV proteins responsible for IFN antagonistic activity. 
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Chapter 2.  Key Molecular Techniques 
 
In this project we have investigated interactions between ISAV proteins and salmon immune-
related proteins. First, a screening was done using the Yeast-two-Hybrid technology, and 
second potential strong interactions were further explored by co-immunoprecipitaion studies. 
This chapter gives an overview of these two key molecular techniques. 
 
 
2.1 Yeast-two-Hybrid (Y2H) 
 
The yeast-two-hybrid (Y2H) technology was developed by Fields & Song, 1989, in the late 
1980s as a method for detection of protein–protein interactions. The Y2H uses the GAL4 
transcriptional activator of the yeast Saccharomyces cerevisiae. Today the method is routinely 
used for large-scale identification of protein-protein interactions. The detection of interactions 
in Y2H is based on the activation of downstream reporter genes. As illustrated in Figure 7, 
these are activated when the DNA binding domain (BD) and the activation domain (AD) of 
the transcription factor, fused to the proteins of interest, are brought together. The BD is the 
domain responsible for binding to an upstream activation sequence (UAS) and the AD is the 
domain responsible for the activation of transcription (Fields & Song, 1989 ). The UAS 
binding triggers the transcription of a reporter gene, which makes yeast colonies grow on 
selective agar. Y2H vectors are designed to express “bait” genes in the BD vector, and the 
other gene of interest, the “prey”, in the AD vector. The “bait” is often a known protein while 
the “prey” is usually an unknown protein. These vector constructs are transformed and 
expressed in two separate Saccharomyces cerevisiae yeast strains that lack the biosynthesis of 
certain amino acids. When grown on media that lacks these nutrients, the yeast fail to 
survive.. See figure 7 for an illustration of the Y2H principle. 
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The Y2H technology has developed and is now used both for the screening of expression 
libraries for protein-protein interactions and also to study interactions between candidate 
proteins (Estojak, et al., 1995).  This last approach is stated to provide less interference of 
false positives. 
 
 
 
 
Figure 7. The yeast-two-hybrid principle is initiated by an interaction between the activation domain (AD) 
“prey” protein and the binding domain (BD) “bait” protein. This fulfils the characteristics of the BD as a 
transcriptional factor. The BD protein binds to the upstream activating sequence UAS for downstream 
transcription of the reporter gene. 
 
Selective media are used to positively select for the cells that host a successful interaction 
between the bait and pray proteins and to test the stringency of the interaction. This involves 
culturing the transformed yeast on media lacking amino acid nutrients. Selective media 
lacking two amino acids, Leucine and Tryptophan, are called double dropout (DD) media. 
Selective media lacking Leucine, Tryptophan, and Histidine is referred to as triple dropout 
medium (TDO), while the media lacking Leucine, Tryptophan, Histidine, and Adenine is 
known as quadruple dropout medium (QDO). Growth on DD media indicates that the mating 
of pray and bait has occurred, growth on TDO indicates a weak interaction, while growth on 
QDO represents a strong interaction between bait and pray (James, et al., 1996). 
 
Findings generated by Y2H are known to contain both false negatives and false positives 
caused by an overexpression of fusion proteins in the yeast nucleus. False negatives are 
generated by non-specific interactions while false positives are generated by detection of 
protein-protein interactions in yeast cells that in reality are never present in the same cell 
(Deane, et al., 2002). This high rate of false findings suggests that interactions found using the 
Y2H technique should be verified with other assays, such as co-immunoprecipitation 
(Pedersen, et al., 2007). 
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2.2 Co-Immunoprecipitation (Co-IP) 
 
 
Co-immunoprecipitation (co-IP) is widely used for analysis of protein-protein interactions. 
The method of co-IP includes several steps. First, the vectors expressing the proteins X and Y 
are transfected in a host cell so that a possible interaction between X and Y can occur. The 
detection of proteins by co-IP is performed after cell lysis, which preserve the interaction. 
Next, an antibody against a specific target protein is coated on a beaded support such as 
Dynabeads (Invitrogen Dynal As, Oslo, Norway) to make an antibody-bead complex. This 
complex is incubated with the sample containing the proteins X and Y. The antibody-bead 
complex will then bind to the protein antigen directly or to an expressed tag coupled to the 
antigen, arranging an antigen-antibody-bead complex (figure 8). This complex is precipitated 
and proteins not precipitated are discarded. 
 
 
 
Figure 8: A simplified picture of co-precipitated proteins. Here the protein tags green fluorescence (GFP) is 
used for precipitation sometimes referred to as pull-down of the protein-protein interaction between protein X 
and protein Y.  
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The proteins and the antibodies are removed from the bead solid support (figure 9) using 
denaturing buffer and boiling. The proteins are identified through further analysis of the 
protein tags or antigens using SDS-PAGE in combination with Western Blot. The advantage 
of using tagged proteins is that you can use the same antibody for detection of several proteins 
while the protein antigen detection requires a unique antibody. However, tags might disturb 
the native function of the protein and other proteins might even bind the tag (Phizicky & 
Fields1995).  
 
 
 
Figure 9: A simplified picture of lysed co-precipitated interaction complex contains fragments of α-antibodies 
and separates protein Y from protein X. 
 
 
 
Immunoprecipitation can be performed with single precipitations (IP) focusing on the antigen, 
while co-IP focuses on the protein interacting with the antigen protein. Co-IP performs a ”pull 
down” with the Dynabead-antibody-complex, which binds to a known protein in a protein 
complex. This ”pull down” also enables the identification of other members of the protein 
complex. However, co-IP studies may require several rounds of precipitation with different 
antibodies because proteins in complexes could hide the antigen/tag. Due to this, some studies 
have focused on first screening for protein interactions with Y2H and then verification of the 
findings from Y2H using co-IP with two known candidate proteins. For validation of the 
protein-protein interactions the use of proper controls is essential to assure the exclusion of 
false positive findings (Sambrook & Russel 2001). 
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Chapter 3 Materials 
 
3.1 Chemicals 
 
Table 2:  List of chemicals and their suppliers with catalogue number 
Name Supplier 
DNA ladder 1kb  
New England Biolabs, Ipswich, MA, USA. Cat. No. 
N3232L 
DOBA (powder) 
MP Bio medicals, Illkirch, France. Cat. No.  4026-
032 
Dulbecco’s Modified Eagle’s Medium (DMEM) Lonza, Verviers, Belgium. Cat. No.  BE12-614F 
Ethanol Arcus kjemi As, Vestby, Norway. Cat. No. 4196 
Foetal Bovine Serum (FBS) 
Invitrogen, Auckland, New Zealand. Cat. No.  
10270-106 
Gentamycin Sulphate (DMEM Ab) Lonza, Verviers, Belgium. Cat. No.  17-518L 
Immune-star WesternC kit 
BioRad, 2000, Hercules CA, USA Cat. No.  170-
5070 
Isopropanol Arcus kjemi As, Vestby, Norway. Cat. No. 300665 
L-Glutamine 200mM in 0,85% NaCl Lonza, Verviers, Belgium. Cat. No.  BE17-605E 
L-Histidine (His), ≥98% Sigma, St. Louis, MO, USA. Cat. No.  H-8125 
LIpofectamine 2000 
Invitrogen Carlsbad, CA, USA. Cat. No.  11668-
027 
Methanol 2,5L 
Merck, Darmstadt, Germany. Cat. No 603-001-00-
X 
Milk powder Tine, Oslo, Norway 
OptiMEM 
Invitrogen, Auckland, New Zealand. Cat. No. 
31985-047 
Ponceau S solution 0,1% 
Sigma life science, St. Louis, MO, USA Cat. No.  
P7170 
Precision Plus protein, dual colour standard, 
500ul BioRad, Hercules, CA, USA. Cat. No. 161-0374 
Precision Plus protein, protein Western C 
standard, 250ul BioRad, Hercules, CA, USA. Cat. No. 161-0376 
Quadruple Dropout (QDO) media, lacking Leu, 
Trp, His and Ade 
Clonetech Laboratories, Mountain View, CA, USA 
Cat. No 630428 
SOC medium 
Invitrogen, Auckland, New Zealand. Cat. No. 
15544-034 
Trypsin EDTA buffer 200mg/L Lonza Verviers, Belgium. Cat. No. BE17-161E 
Yeast media lacking Leucine (Leu) 
Clonetech Laboratories, Mountain View, CA, USA. 
Cat. No.  630414 
Yeast media lacking Trypthophan (Trp) 
Clonetech Laboratories, Mountain View, CA, USA. 
Cat. No.  630413 
Triple Dropout (TDO) media, lacking Leu, Trp MP Biomedical, Illkirch, France, Cat. No.  4530-
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and His 122 
XT Mops Criterion running buffer 20 x BioRad, Hercules, CA, USA. Cat. No.  161-0788 
Dynabeads Protein G 
Invitrogen Dynal As, Oslo, Norway Cat. No. 100-
04D 
GelRed Nucleic Acid Gel Stain, 10,000X in water BIOTIUM, Hayward, CA. Cat. No. 41003 
 
3.2 Kits and enzymes 
 
Table 3: List of Kits, enzymes, buffers and their suppliers with catalogue number 
Name Supplier 
Frozen-EZ Yeast transformation II kit Zymo Research, USA. Cat. No. T2001 
Gateway BP Clonase II Enzyme Mix Invitrogen, Carlsbad, USA. Cat. No. 11789-020 
Gateway LR Clonase II Enzyme Mix Invitrogen, Carlsbad, USA. Cat. No. 11791-020  
Pfu Ultra II Fusion HS DNA Polymerase Stratagene, La Jolla, CA, USA. Cat. No. 600670  
Proteinase K solution Invitrogen, Carlsbad, USA. Cat. No. 25530-049  
Quick gel extraction and PCR purification Combo 
kit 
Invitrogen, Carlsbad, USA. Cat. No. K220001 
Western C solution kit BioRad, Hercules, CA, USA. Cat. No. 170 5070 
PureLink HiPure Plasmid DNA Midiprep Kit Invitrogen, Carlsbad, USA. Cat. No. K2100-14 
Zymoprep Yeast Plasmid Miniprep II Zymo Research, Irvine, CA, USA. Cat. No. 
D2004   
 
3.3 Vectors, primers 
 
Table 4: List of vectors and their suppliers with catalogue number. 
Name Supplier 
pENTER directional Topo cloning Invitrogen, Carlsbad, USA. Cat. No. 
K2400-480 
pDEST-Myc expressions vector, (UIT modified) from  
pcDNA-DEST47 vector 
Invitrogen, Carlsbad, USA Cat. No. 
12281-010  
pDEST-GFP expression vector (pDEST-47) Invitrogen, Carlsbad, USA Cat. No. 
12281-010 
pGBKT7-BD Vector, (pGBD) Binding domain, (fusion 
binding) c-Myc tag Kanamycin resistance 
Clontech, Laboratories, Mountain View, 
CA, USA. Cat. No.  630443 
pGADT7 AD Vector, (pGAD) Activation Domain, (fusion 
activation domain) HA tag Ampicillin resistance 
Clonetech, Laboratories, Mountain View, 
CA, USA. Cat. No. 630442 
pDONR207 vector Invitrogen, Carlsbad, USA Cat. No 
12536017 
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Table 5: List of sequences primers. Invitrogen delivered all primers. 
Application Primer Name Primer Sequence 
Y2H expression vector  pGAD_fwd GTCAAAGACAGTTGACTGTA 
pGAD_rev GAGTCACTTTAAAATTTGTAT 
pGBD_fwd TATTCGATGATGAAGATACC 
pGBD_rev AAAACCTAAGAGTCACTTTAA 
IP expression vector pDEST-GFP_fwd TGGAGTTCGTGACCGCCG 
 
3.4 Solutions 
 
Table 6: Solutions with recipes 
Solutions Recipe 
Blot buffer (tris, glycine) 20% MeOH 30g. tris base, 144g Glycine and 8ooml distilled 
H20 
Glycerol for yeast construct -80C stocks Heart Infusion Broth 2,125g, Distilled H2O 85ml 
and Glycerine 15ml were mixed and aliquot in 2ml 
tubes. 
Milliqwater Reverse osmosis and UV treated H20 
Nonidet-P40 (NP40) lysis buffer 
 
13.7ml 50mM NaCl, 1.0% NP-40 and 6.67ml 
50mM Tris. Mixed by magnetic sterer, filled to 
500ml with with distilled H20. pH adjusted til 8.0.  
YEPD 10g Yeast extract, 20g Peptone and 20g Glucose 
were mixed and filled up with distilled H20 till 
1liter.  
3x Sample buffer (SB) with 100mM DTT 7,2ml 1M Tris-Cl, 9ml 20% Sodium Dodecyl 
Sulfate (SDS), 9ml 100% Glycerol, and 0,018g 
Bromophenol blue, were mixed with distilled H20 
to a volume of 30ml. The pH was adjusted to 8,3. 
LB-agar Ampicillin 100 µg/ml  37g LB-agar were disolved and adjusted with 
distilled H20 til 1 litre. The solution were mixed 
with magnetic stearer, autoclaved.and cooled to 
50°C before adding 100mg Ampicillin. The liquid 
was poured into 10cm plates and the plates were 
stored at 4°C when set. 
LB-agar Kanamycin 50 µg/ml The same as above but adding 50mg Kanamycin 
for resistance. 
LB-liquid media 5g yeast extract, 10g tryptone, 10g NaCl and 15g 
bacto agar were dissolved and adjusted with 
distilled H20 till 1 litre. The solution were mixed 
with magnetic stearer, autoclaved and cooled to 
50°C before stored at 4°C 
Quadruple dropout (QDO) DOBA agar 43,7g DOBA, 0,59g Leu/Trp/His/Ade were 
dissolved and adjusted with distilled H20 till 1 litre. 
The solution were mixed with magnetic stearer, 
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autoclaved and cooled to 50°C poured into 10cm 
plates and the plates were stored at 4°C when 
set 
Triple dropout (TDO) DOBA agar The same preparation as above but adding 0,62g 
Leu/Tarp/His, instead of the above aminoacids. 
Double dropout (DD) DOBA agar The same preparation as above but adding 0,62g 
Leu/Trp/His + 0,2g Histidine. 
Double dropout liquid (DD) DOBA media Same as for DD agar but 27g DOB were used 
instead of DOBA 
Single dropout Leucine 27g DOB 0,69g Leu were dissolved and adjusted 
with distilled H20 till 1 litre. The solution was 
mixed with magnetic stearer and autoclaved. 
Single dropout Tryptophan Same as above but 0,74g Trp were used. 
Phosphate- buffered saline (PBS) de Boer Na2HPO4 x 2H2O 1,34g, NaH2PO4 x H20 0,34g 
and NaCl 8,5g and filled up with distilled H20 till 
1liter. The solution was mixed with magnetic 
stearer and autoclaved. 
Phosphate- buffered saline (PBS) with 0,1% 
Tween 20 
NaCl 8 g, KH2PO4 0,2 g, Na2HPO4 x 2H2O 1,49 g, 
KCl 0,2 g, and 1ml tween 20 were mixed and 
filled up with distilled H20 till 1liter. The pH was 
adjusted till 7,5. 
10 X TBE buffer 55g Boric acid, 40ml EDTA and 107g Tris base 
were mixed and filled up with distilled H20 till 
1liter. The pH was adjusted till 8. 
 
3.5 Biological material 
 
Virus 
Table 7: Virus, all are ISAV4 isolates (Glesvær outbreak), provided by NVI. (Markussen et 
al., 2008) 
Segment Protein GenBank access number 
(complete cds) 
1 PB2 DQ785178 
2 PB1 DQ785192 
3 NP DQ785206 
4 PA DQ785220 
5 F DQ785234 
6 HE DQ785248 
7 Non-structural protein 1 and 2 DQ785262 
8 Non-structural protein and matrix protein genes DQ785276.1 
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Innate immune system sequences from Atlantic salmon  
 
Table 8: List of characterized genes of Atlantic salmon innate immune system sequences with 
accession number to GenBank, (the Gateway plasmid constructs with table 8 gene sequences 
incorporated, where also provided by UIT). 
Gene	  (Salmo salar) 
GenBank accession 
number Reference 
Interferon regulatory factor 3 
(Irf3) FJ517643 (IRF3) (Bergan, et al., 2010) 
Interferon regulatory factor 7 
(Irf7a) EU153263 (IRF7A) (Kileng et al., 2009) 
Interferon regulatory factor 7B 
(Irf7b) FJ517644 (IRF7B) (Bergan, et al., 2010) 
LOC100302030 TLR8-like 
(Trl8) NM_001161693 (Skjæveland, et al., 2009) 
Myeloid differentiation primary response gene 
(88) 
(myd88) EF672332 (Skjæveland et al., 2009) 
Stat1 Salmo salar stat1a mRNA, complete cds 
(Stat1a) GQ325309 (Skjesol, et al., 2009) 
Tlr9 toll-like receptor 9 
(Trl9) NM_001123653   (Skjæveland, et al., 2008) 
TIR-domain-containing adapter-inducing 
interferon-β 
(TriF)  Unpublished  
 
Cell lines 
Table 9: List of Cell lines and their suppliers with catalogue number 
Cell line Supplier 
Human Embryo Kidney (HEK) 293T 
Cells 
ATTC, NY, USA. Cat. No.  CRL-11268 
PJ69-2A Saccharomyces cerevisiae Clonetech, Laboratories, Mountain View, CA, USA. 
Subcloning Efficiency DH5 α cells Invitrogen, Carlsbad, USA. Cat. No.18265-017 
Y187 Saccharomyces cerevisiae Clonetech, Laboratories, Mountain View, CA, USA. 
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Antibodies 
Table 10: List of Antibodies and their suppliers with catalogue number 
Antibody Supplier 
Goat anti Mouse –HRP 1:4000 Invitrogen. Eugene, Oregon, USA. Cat. No.  
62-6520 
Goat anti Rabbit –HRP 1:2000 Invitrogen. Eugene, Oregon, USA. Cat. No.  
G21234 
Mouse anti Hemagglutinin (HA) 1:250, Invitrogen. Eugene, Oregon, USA.  Cat. No.  
326700 
Mouse anti-c-Myc Antibody, 1:5000 Invitrogen. Eugene, Oregon, USA. Cat. No.  
13-2500  
Precision Protein StrepTactin-HRP Conjugate, BioRad, Hercules, CA, USA. Cat. Cat. No.  
161-0380 
Rabbit anti Hemagglutinin (HA) 1:500  Invitrogen. Eugene, Oregon, USA. Purified, 
Cat. No.  71-5500 
Rabbit anti-GFP Antibody 1:2000 Invitrogen, Eugene, Oregon, USA. Cat. No.  
A-11122 
 
3.6 Laboratory equipment 
 
Table 11: List of technique, instrument and their suppliers 
Technique Instrument Producer 
Centrifugation CS-6R 
Microfuge 22R 
Beckman coulter, Pasadena, CA, 
USA. 
Beckman coulter, Pasadena, CA, 
USA. 
Conventional PCR DNA Engine peltier thermal cycler MJ research, Waltham, MA, USA 
Immunoprecipitation Cell culture plates, 6well Corning incorporated. Corning, NY, 
USA. Cat. No. 3506 
Incubation 
 
Shaker S3 
Unimax 1010DT integrated with 
Unimax 1000 4.1.11 
Steri-cycler 37˚C CO2-incubator 
Digital dry bath D1200 
Medkjemi AS, Norway. 
 
Heidolph, Schwabach, Germany. 
Thermo, Mariette, Ohio, USA. 
Labnet, Woodbridge, NJ, USA. 
Microscopy Fluorescence microscope LEICA DM 
IL  
Stereomicroscope 
LEICA microsystems, Wetzlar, 
Germany. 
Leitz Laboveit, Wetzlar, Germany 
RNA/DNA analysis Nano drop 2000 spectrophotometer Thermo 
Western blot Immobilon Molecular Imager  
 
ChemiDoc XRS+ 
Western Blot chamber  
Blotting chamber 
Powerpac 200 
Criterion XT precast SDS-PAGE gel, 
10% Bis-Tris, 18well 
Millipore Corporation Bedford, MA, 
USA, cat no IPVH00010 
BioRad, Hercules, CA, USA. 
BioRad, Hercules, CA, USA. 
BioRad, Hercules, CA, USA. 
BioRad, Hercules, CA, USA. 
BioRad, Hercules, CA, USA  
Cat. No. 345-0112 
3. Materials 
 34 
3.7 Software 
 
Table 12: List of software and sources 
Name Source 
BLAST (Altschul, et al.,1990)  
http://blast.ncbi.nlm.nih.gov/ 
CLC Main Workbench (Weaver, et al., 2009) 
 Aarhus, Denmark. 
Expasy  (Gasteiger, et al., 2003) 
http://ca.expasy.org/tools/pi_tool.html 
Multicoil  (Wolf, et al., 1997) 
http://www.osc.edu/supercomputing/ 
software/apps/multicoil.shtml 
Paircoil (Berger, et al., 1995) 
http://groups.csail.mit.edu/cb/paircoil/paircoil.html 
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Chapter 4. Methods 
 
4.1 Gateway cloning of Atlantic salmon and ISAV genes 
 
Gateway cloning was used for preparation of expression vectors later used to screen for 
protein-protein interactions with Yeast-two-hybrid, followed by verification of the findings 
using co-immunoprecipitation. Both methods require candidate genes cloned in suitable 
Gateway vectors, these procedures were maintained in an attempt to find key interactions 
responsible for the Interferon antagonistic characteristics of ISAV (GarcÌa-Rosado et al., 
2008). 
 
4.1.1	   	  Expression	  vectors	  
 
This study focuses on proteins that have been hypothesized to suppress the innate immune 
system in mammals. Nearly all of the expression vectors that express these proteins and 
enable in vivo protein-protein interaction analysis in eukaryotic cells were provided by NVI 
and UIT. The ISAV 4 (Glesvær outbreak) isolate segment inserts are listed in table 7, section 
3.5. They were provided by the NVI in suitable vectors for both Yeast-two-hybrid (Y2H) and 
Immunoprecipitaion (IP). Vectors with inserts of expressed salmon immune-related proteins 
(table 8,section 3.5) were provided by the UIT, in suitable vectors for both Y2H and IP. In 
order to compliment the provided ISAV inserts that were not expressed, ISAV segments 5 
and 6 were made Gateway cloning compatible for this study. Initially, primers were designed 
for cloning into the pENTR vector. 
 
4.1.2	   Primer	  design	  for	  Gateway	  cloning	  
 
The initial step towards getting each ISAV segment into the Gateway compatible entry vector 
was to design primers for directional cloning into the pENTER/D-TOPO vector (Invitrogen, 
Invitrogen, Carlsbad, USA.). The pENTR vector was used as an entry clone to Gateway 
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cloning enabling vector inserts in suitable vectors for protein interaction analysis, see figure 
10. The directional cloning ensures the proper orientation of the inserts by adding 5´CACC 
upstream of the ATG initiation codon in the forward primer that base pair with the overhang 
sequence GTGG in the pENTR vector. A stop codon was incorporated in the end of the 
reverse primer if the inserted gene did not have one. To compliment the not expressed vector 
insert from the ISAV membrane segments 5 and 6, primers were designed for these segments 
without the trans-membrane region. The primers are shown in table 13. 
 
Table 13. Oligonucleotide primers used for PCR amplification and cloning of the ISAV 
membrane genes  
Primer name  Nucleotide sequence (5´-3´) 
HE_FWD          CACCATGGCACGATTCATAATTTTATTC  
HE_REV      TTAATTCCCAGATGTTGCTGC  
HE_REV      TTAAGCTGAACCATGTAGTGAG  
F_FWD   CACCATGGCTTTTCTAACAATTTTAGT  
F_REV  TTAACCTCCACCCTAATCCCTT 
F_REV     TTAACCGCCTCAAGGGCTCCTT  
Sequence representing recognition sites at the segment 5(F) and 6(HE). The underlined sequence is necessary for 
directional cloning that base pair with GTGG in the pENTR vector.  The bold letters represent start and stop 
codons.  
 
4.1.3	   Polymerase	  chain	  reaction	  (PCR)	  for	  the	  pENTR	  vector	  
The next step towards cloning ISAV segments in Gateway compatible vectors was to amplify 
the ISAV inserts 5(F) and 6(HE) from a DNA plasmid, listed in table 7, section 3.5. The 
amplification was performed by PCR using the PfuUltra II fusion HS kit, (Stratagene La Jolla, 
CA, USA.). The PCR reaction volumes and the PCR program are showed below in table 14. 
 
Table 14: PfuUltra II fusion HS reaction volumes 
Distilled water (dH2O)              40.5 µl 
10× PfuUltra® II reaction buffer       5.0 µl 
dNTP mix (25 mM each dNTP)       0.5 µl 
DNA template (100 ng/µl)        1.0 µl 
Primer #1 (10 µM)         1.0 µl 
Primer #2 (10 µM)         1.0 µl 
PfuUltra® II fusion HS DNA polymerase     1.0 µl 
Total reaction volume          50.0 µl 
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PCR reaction was run on the DNA Engine peltier thermal cycler (MJ Research, Waltham, 
MA, USA) using the PCR program outlined beneath in table 15. 
 
Table 15: Conditions for PfuUltra II fusion HS amplification 
Number of cycles   Temperature  Duration 
1 Activation   95°C  2 minutes 
30 Denaturation   95°C  20 seconds 
 Annealing   55°C  20 seconds 
 Elongation   72°C  15 seconds 
1       8°C  ∞ 
 
The PCR reaction products were run on an agarose gel electrophoresis separating the 
amplicons depending on nucleotide size. The procedure is described in the following text. 
 
Agarose gel electrophoresis 
 
1. A 1,5% agarose gel with 1xTBE buffer was prepared and the agarose dissolved by 
heating in microwave. 
2. The Gel red, (BIOTIUM, Hayward, CA. USA.) was added to the solution for a 1:10 000 
dilution. 
3. The solution was poured into a gel mould with a comb, after the gel had stiffened the 
comb was removed and the gel was placed in a gel chamber. 
4. The samples were mixed in a loading buffer (6:1) and loaded into the gel chambers made 
by the comb, together with 1kb DNA ladder. 
5. The gel was run at 90Volt for 60minutes. 
6. Visualizing of the PCR fragments on the gel was performed using the UV light 
application of ChemiDoc XRS+ (BioRad, Hercules, CA, USA.). 
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If multiple bands were amplified the fragment of expected size was cut out from the gel and 
purified with a gel extraction kit (Quick gel extraction, Invitrogen, Carlsbad, USA.). The 
procedure is described stepwise below. 
 
 
Gel extraction, (Invitrogen, Carlsbad, USA). 
 
1. Gel pieces of the wanted PCR fragment with a weight > 400mg were incubated with the 
Gel solubilisation buffer (L3) in a water bath at 50 °C for at least 15minutes, dissolving 
the gel piece. The gel solution was loaded into the centre of a PureLink® Clean-up Spin 
Column and placed in a 2ml tube. 
2. A Centrifugation step at >10,000 × g for 1 minute was followed by discarding the flow-
through and adding 50 µl wash buffer (W1). This was followed by another centrifugation 
step at >10,000 × g for 1 minute. The flow-through was discarded. 
3. To remove any residual wash buffer and ethanol, centrifugation at maximum speed was 
performed for 2–3 minutes. The wash tube was discarded and the PureLink Spin Column 
placed into an elution Tube. 
4. For elution 50µl elution buffer (E1) was added to the centre of the PureLink Spin Column 
placed in a new tube and incubated for 1 minute at room temperature. A centrifugation 
step at >10,000 × g for 1 minute, obtained the purified DNA in the new tube. The DNA 
was stored at -20°C  
 
When a single concentrated PCR product of the desired length was visualized after gel 
electrophoresis, PCR purification was used (PCR purification Combo kit, Invitrogen, 
Carlsbad, USA.). The procedure is described below. 
 
PCR purification, (Invitrogen, Carlsbad, USA). 
 
1. Four volumes of Binding Buffer (B2) were added to one volume of PCR reaction and 
mixed well. 
2. The PureLink Clean-up Spin Column was placed in a 2ml tube. The solution was 
centrifuged in room temperature at 10,000 × g for 1 minute, the flow through discarded. 
3. Then, 650µL of Wash Buffer was added to the PureLink Spin Column. The solution was 
centrifuged in room temperature at 10,000 ×  g for 1 minute, then the flow-through was 
discarded.  
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4. At last, an additional centrifugation step at maximum speed, 2–3 minutes at room 
temperature, was performed to remove any residuals. 
5. Samples were then ready for elution by the elution Buffer (50 µL), which was added to 
the centre of the PureLink® Spin Column, placed in a new tube. The samples were 
incubated at room temperature for 1 minute. This was followed by centrifugation at 
maximum speed for 1 minute, to obtain the purified PCR product. The purified DNA was 
stored at 20°C. 
 
The isolated and purified PCR products were inserted into the pENTR vector as an entry 
clone for Gateway cloning. That enables desired inserts in suitable vectors for protein-protein 
interaction analysis with Y2H and IP analysis. 
 
4.1.4 Cloning	  into	  pENTR	  D-­‐TOPO	  vector	  (Entry	  clone)	  
 
The pENTR cloning enables further site-specific recombination cloning. It takes advantage of 
the site-specific recombination properties of bacteriophage lambda (Landy, 1989), that 
recombinants the entry clone insert (gene) of interest into suitable vectors, as illustrated in 
Figure 10.  
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Figure 10. Gateway cloning starting with the pENTR as an entry clone that enables the cloning of gene inserts 
to a destination (pDEST) vector. The four different kinds of pDEST vectors were used as expression vectors for 
protein-protein interactions studies. 
 
These vectors were used for transfection into Y2H cells (Y187/ PJ69) for Y2H analysis, and 
into human cells (HEK293T) for co-IP analysis. All plasmid constructs were sequenced 
(Macrogen, Korea), and verified with CLC Main Workbench. 
 
Expression vectors pGBD and pGAD were transfected into Saccharomyces cerevisiae cell 
line PJ69-2A and Y187, both from Clonetech Laboratories (Mountain View, CA, USA). The 
pGAD and pGBD transfections were used for Yeast-two-hybrid (Y2H) analysis. For the IP 
analysis, the expression vectors pDEST-GFP and pDEST-Myc were transfected into Human 
embryonic kidney 293T cells (ATTC, NY, USA). The transfer of gene inserts between 
pENTR vector and pDEST vector was performed using recombination by LR Clonase ™ II 
enzyme (Invitrogen, Carlsbad, USA.). The LR reaction procedure is listed below. 
 
The LR Reaction 
1. In a 1,5ml tube 1 µl of the pENTR and 1 µl of the pDEST vector along with 8 µl TE 
buffer were added at room temperature, followed by easily mixing the solution by 
pipetting. 
2. The LR Clonase ™ II enzyme was put on ice along with the samples and the vector 
solution, for about 2 minutes. 
3 The LR Clonase II enzyme was mixed briefly using vortex, before 2 µl of LR Clonase 
II enzyme mix was added to each reaction and mixed by vortex briefly.  
4. Briefly centrifugation to gather the liquid in the bottom of the tube was followed by 
incubation of the reactions at 25°C for 1 hour. 
5 To terminate the reaction 1 µl of the Proteinase K solution was added, briefly vortexed 
and incubated at 37°C for 10 minutes. 
 
All pDEST vectors with a gene of interest inserted were designed as expression vectors and 
transformed in to DH5α Subcloning efficiency cells (Invitrogen, Carlsbad, USA) for the 
expression of the desired genes. The procedure is described below. 
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Transformation of Gateway vectors  
 
1. The DH5α were thawed on wet ice together with 1,5ml tubes for pre cooling, 1 µl of 
DNA was added to 25µl DH5α cells and gently mixed. Cells and DNA were incubated 
on ice for 2minutes. 
2.  The cell solution was heat shocked in 30s at 42°C and quickly incubated on ice for 2 
minutes. 
3. The next step was adding 250µl SOC medium to the solution, which was then incubated 
on 225rpm shake at 37°C for 1hour.  
4. Finally, 50 µl of the transformation mix was plated on LB plates containing 100 µg/ml 
kanamycin for the pENTR D-TOPO, and the pGBD vector. LB plates with 100 µg/ml 
ampicillin were used for the pDEST vectors and the pGAD vector. The LB plates were 
incubated at 37°C overnight before the bacterial colonies with the wanted gene inserts 
incorporated were selected for further investigation.  
 
Preparation of pDEST vectors  
 
The plasmid preparation of pDEST vectors was performed with the PureLink HiPure Plasmid 
DNA Midiprep Kit (Invitrogen) resulting in high quality plasmid DNA. Starting from 25 mL 
overnight E. coli colonies cultures transformants were picked from an appropriate resistance 
agar plates. 
 
1. Bacterial culture cells were harvested by centrifugation at 4,000 ×  g for 10 minutes, the 
residual medium was discarded. 
2. Resuspension Buffer (R3) with RNase A was added to an amount of 10 mL to the cell 
pellet for resuspention of the cell pellet.  
3. For cell lysis, 10 mL Lysis Buffer (L7) was added and mixed gently by inverting the 
capped tube until the lysate mixture was homogenous. The lysate was incubated at room 
temperature for 5 minutes. 
4. 10 mL Precipitation Buffer (N3) was added, and mixed by inverting the tube until the 
solution was homogeneous.  
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5. The precipitated lysate was transferred into the HiPure Filter Midi Column and then 
passed through the filter by gravity flow. The flow-through was discarded.  
6. After the HiPure Filter Midi Column stopped dripping, the filtration cartridge was 
removed and discarded. 
7. The midi column was washed with 20 mL wash buffer (W8) and the flow-through was 
discarded. 
8. For the elution of DNA a new tube was placed under the HiPure Filter Midi column, and 
5 mL elution buffer (E4) added. The flow-trough contains the DNA. 
9. Precipitation of DNA was performed by adding 3.5 mL of Isopropanol (Arcus, 
Hummelstown, PA, USA) to the DNA. The DNA-isopropanol mixture was incubated for 
2 minutes at room temperature. 
10. The DNA-isopropanol mixture was centrifuged at 12,000 × g for 30 minutes at 4°C. and 
the supernatant was discarded. 
11. The DNA pellet was resuspended in 3 mL 70% ethanol (Arcus, Hummelstown, PA, 
USA), and centrifuged at 12,000 × g for 5 minutes at 4°C. The supernatant was carefully 
removed and discarded. 
12. The pellet was air-dried for approximately10 minutes. 
13. The DNA pellet was resuspended in 200 µl TE Buffer and the purified DNA stored at  
 –20°C. 
 
4.2. Screening for protein-protein interactions using Yeast two 
Hybrid (Y2H) 
 
After the preparations of suitable expression vectors for Y2H was performed the actual study 
began with screening of protein-protein interactions. Screening were performed to identify 
novel protein-protein interactions between ISAV proteins and proteins from the innate 
immune system of Atlantic salmon. In addition protein-protein interactions within the ISAV 
proteins were analysed.  
 
4.2.1	   Expression	  vectors	  for	  Yeast-­‐two-­‐hybrid	  	  
 
Genes of interest regarding Interferon antagonistic activity were cloned into the pENTER D-
TOPO vector (Kanamycin resistance), and subcloned by LR clonase recombination 
4. Methods 
 43 
(Invitrogen) into eukaryotic expression vectors. Modified Clontech vectors (pGADT7 and 
pGBKT7) were used (Pedersen, et al., 2007 ) and named the pGAD and the pGBD vector, 
shown in Figure 10. The pGAD vector was then suitable for Y2H analysis. The other Y2H 
vector, the pGBD, was constructed with the LR reaction from pENTR to pDONR207 vector 
with Gentamycin resistance for selection. The BP reaction was used to recombine the insert 
back to pENTR, followed by LR reaction into pGBD. The BP reaction procedure is listed 
below. 
 
The BP Reaction      
1. In a 1,5ml tube 1 µl of the pENTR and 1 µl of the pDONR 207 vector along with 8 µl TE 
buffer were added at room temperature, followed by easily mixing the solution by 
pipetting.   
2. The BP Clonase ™ II enzyme was put on ice along with the samples and the vector 
solution, for about 2 minutes.   
3 The BP Clonase II enzyme was mixed briefly with vortex, before 2 µl of BP Clonase II 
enzyme mix was added to each reaction and mixed by vortex briefly.  
4. Incubation of the reactions at 25°C were made for 1 hour after a briefly centrifugation to 
gather the liquid in the bottom of the tube. 
5 To terminate the reaction 1 µl of the Proteinase K solution were added, briefly vortex and 
incubated at 37°C for 10 minutes. 
 
The pDONR 207 pathways are needed because both pENTR and pGBD have kanamycin 
resistance that makes it hard to distinguish the pENTER colonies from pGBD colonies on the 
agar plate after transformation. Now, the pGBD vector and the pGAD vector were picked as 
colonies after transformation from Kanamycin and Ampicillin resistance LB plates, 
respectively. The pGBD expression vectors were then prepared by minipreparation as the 
other pDEST vectors in section 4.1.4. Further applications towards Y2H analysis the Y2H 
expression vectors were transfected into yeast cells, the procedure is listed below. 
 
Transfection of Yeast PJ69-2A and Y187 Saccharomyces cerevisiae strains 
 
1. Preparation of competent Saccharomyces cerevisiae, PJ69-2A and Y187 were performed 
by growth of the cells at 30˚C in 10ml YEPD broth to mid log phase (OD600 of 0.8-1.0) 
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2. The overnight cells-culture was pelleted at 500x g for 4 minutes and supernatant 
discarded, followed by washing the cells with 10ml of EZ 1 solution.  
3. The cells were re-pelleted and supernatant discarded, followed by resuspending the pellet 
in 1ml of EZ2 solution. 
4. Competent yeast cells were mixed with 0,2-1 µg DNA, PJ69-2A for the pGBD vector and 
Y187 for the pGAD vector, and 500µl EZ 3 solution and incubated at 30 °C for 
45minutes in a 225rpm shake incubator. 
5. The transfection mixture was spread in an amount of 150 µl on DOBA plates, lacking 
leucine for pGAD, and lacking Tryptophan for pGBD, and incubated for 2-4 days. 
 
For storage, sequencing and the Yeast-two-hybrid study, preparation of yeast plasmids were 
performed by Zymoprep™ Yeast Plasmid Miniprep II (Zymo Research), as described below. 
The enzyme Zymolase used for yeast plasmid preparation has a specific lytic digestion of 
Saccharomyces cerevisiae cells. 
 
Yeast Plasmid preparation 
1. Aliquots of 1.0 ml of the full-grown yeast cells was added into 1.5 ml tubes and 
centrifuged at 600x g for 2 minutes, the supernatant was discarded.  
2. Solution 1 in an amount of 150 µl was added to each pellet, in addition 2 µl of Zymolyase 
was added, and the pellet was resuspended by easily vortex.  
3. The samples were incubated at 37°C for 60 minutes. 
4. The Solution 2 was added in an amount of 150 µl and mixed well, followed by 
supplement of 150 µl Solution 3. Again the tubes were mixed well,  
5. Centrifugation of the solutions at maximum speed for 2 minutes. 
6. The supernatant where transferred to the Zymo-spin-1 column, the Zymo-spin-1 column 
was centrifuged at 600x g for 30 seconds and the flow-through was discarded.  
7.  The Wash buffer was added to the column and in an amount of 550 µl and centrifuged at 
600x g for 2minutes. The flow-through was discarded. 
8. For elution the Zymo-spin-1 column was put into a new 1,5ml tube and 10 µl of TE 
buffer was added to the column and centrifuged at 600x g for 30 seconds. The yeast 
plasmids were stored at -20°C. 
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4.2.2	   Sequencing	  of	  the	  expression	  vectors	  for	  Yeast-­‐Two-­‐Hybrid	  
 
Primers pGADfwd, pGADrev and pGBDfwd, pGBDrev, were sent together with 30 µl Y2H 
expression vectors in a concentration of 100ng/µl, to Macrogen, Korea, for sequencing. The 
primers are listed with their nucleotide sequence in Table 5. Section 3.3. 
 
Table 15: Yeast-two-Hybrid expression vectors sent for sequencing 
Vector ISAV4 segment 
pGAD 1 
pGAD 3 
pGAD  4 
pGAD  7ORF1 
pGAD 7ORF2 
pGAD  8ORF1 
pGAD 8ORF2 
pGBK  2 
pGBK 8ORF1 
pGBK  IRF3 
pGBK STAT1 
pGBK  TLR9 
pGBK IRF7 
 
 
4.2.3	   Protein	  expression	  analysis	  of	  Y2H-­‐expression	  vectors	  by	  Western	  Blotting	  	  
 
For protein expression analysis, yeast cell lines PJ69-2A and Y187 transfected with pGBD 
vector and pGAD vector, respectively, were grown at 30˚C in 10ml media lacking Tryptophan 
for PJ69-2A (pGBD) and media lacking Leucine for Y187 (pGAD) for 48hours. The cultured 
cells were centrifuged at 500g and the supernatant discarded. Then, the pellet was 
resuspended in 20µl 3X sample buffer (SB) with dithiothreitol (DDT) for yeast cell lysis. The 
samples were boiled for 15 minutes, quickly centrifuged, kepped on ice and subjected to SDS-
PAGE gel (Criterion XT precast SDS-PAGE gel, 10% Bis-Tris, 18well, BioRad, Hercules, 
CA, USA). The SDS-Page electrophoresis procedure is described below. 
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SDS-Page 
1. The SDS-Page gel Criterion XT precast 10% Bis-Tris 18well (BioRad, Hercules, CA, 
USA), was prepared with 1x XT mops Criterion running buffer (BioRad, Hercules, CA, 
USA) in a SDS- Page electrophoresis chamber.  
2. The samples were loaded together with the precision plus protein ladders, Dual colour 
standard, (BioRad) and the protein Western C standard, (BioRad).  
3. All SDS-Page in this study, both for Y2H, IP and Co-IP, were run at 100V for 15minutes 
and an additional 150V for 1 hour. 
 
The next step towards visualising the molecular size of the proteins encoded by the yeast 
expression vectors in yeast cells was to transfer the separated proteins on the SDS-PAGE, on 
to a blot membrane. The blot membrane was then hybridized with primary and secondary 
antibodies diluted in PBS with 0,5% Tween with 1% blocking agent for detection of the 
incorporated expressed tags. The procedure for blotting is outlined below. 
 
 
Blotting  
1. First, the blot membrane Immobilon Molecular Imager (Millipore Corp, USA), was 
prepared by exposure to Methanol (Merck, Darmstadt, Germany) for 5 seconds and 
incubated for 10 minutes in blotting buffer. 
2. The SDS-PAGE was immediately added to the blot membrane and packed with three blot 
papers and one fiber pad on each side, all pre-moisture with blot buffer and clamped in 
the blot sandwich. It was also ensured that no air bubbles had been formed between the 
gel and the membrane. 
3. The blot sandwich was applied between solid supports in the blot chamber filled with 
pre-cooled blot buffer. All blots in this study, both for screening and verification of 
protein-protein interactions, were run at 100V for 1 hour. During this procedure, the 
negative charged proteins migrates towards the positive electrode, but are stopped and 
bound by the blot membrane. 
4. To visualize the successfull transfer between the gel and the blot membrane, the blot 
membrane was placed in 0,1 % Ponceau S solution (Sigma life science, MO, USA), and 
washed in filtered water. 
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5. Unspecific background binding of antibodies was prevented using 5% non-fat milk (Tine, 
Oslo, Norway) diluted in PBS with 0,5% Tween 20, incubated during agitation at room 
temperature by Shaker S3 (Medkjemi AS, Norway), for 1hour at 200rpm.  
6. The incorporated hemagglutinin (HA) tag and the Myc N-terminal tag for pGAD and 
pGBD respectively, were hybridized with primary Rabbit anti-HA antibody (Invitrogen, 
Eugene, Oregon, USA) diluted till 1:500, and Mouse anti-c-Myc antibody (Invitrogen, 
Eugene, Oregon, USA), both incubated at room temperature for 1 hour. 
7. The blot membrane was washed in PBS 0.1% Tween 20 for 2x 15minutes at 200rpm by 
shake incubation in room temperature. 
8. Secondary antibodies Goat anti Mouse –HRP 1:4000 (Invitrogen, Eugene, Oregon, USA) 
and Goat anti Rabbit –HRP 1:2000 (Invitrogen, Eugene, Oregon, USA), was applied for 
pGAD and pGBD respectively and incubated at room temperature for 1hour at 200rpm 
by shake incubation. The incubation mixture of the secondary antibody layer included 
1:10000 dilution of the precision Protein StrepTactin-HRP Conjugate (BioRad, Hercules, 
CA, USA), for visualisation of the precision plus protein ladders. 
9. The blot membrane was washed in PBS 0.1% Tween 20 for 2x 15minutes at 200rpm by 
shake incubation in room temperature. 
10. The Western C solution (BioRad, Hercules, CA, USA) containing hydrogen peroxidase 
were used as a substrate to the conjugated HRP on the secondary antibody, the substrate 
catalyse the oxidation of luminol that emits luminescence. The chemiluminescence was 
detected in a Chemi Doc XRS+ (BioRad, Hercules, CA, USA). 
 
4.2.4	   Mating	  of	  the	  pGBD	  vector	  in	  PJ69-­‐2A	  cells	  and	  pGAD	  vector	  in	  Y187	  cells.	  
 
The plasmid constructs of pGBD vector in PJ69-2A and the pGAD vector in Y187, both two-
hybrid (GAL4) compatible, were grown at 30°C for 48h. They were grown in selective media 
lacking Tryptophan for PJ69-2A with pGBD vector, and lacking Leucine for Y187 with 
pGAD vector. These cells were mated in pairwise combinations of PJ69-2A with the pGBD 
vector including genes of the Atlantic salmon immune system, and Y187 with pGAD vectors 
including clones of the viral segments of ISAV. The haploid transformants were mated using 
500µl of each yeast cell strain and were then incubated at 30°C for 24 hours in rich YEPD 
media, providing a transcriptional assay for detecting protein interactions in vivo in yeast 
cells. The diploid transformants were plated in an amount of 150 µl on DOBA plates with 
double dropout (DD) media lacking Leucine and tryptophan (Clonetech Laboratories, CA, 
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USA), showing if mating has occurred. Growth of triple dropout medium (TDO) lacking 
Leucine, Tryptophan, and Histidine (Clonetech Laboratories, CA, USA), indicates a weak 
interaction and quadruple dropout medium (QDO) lacking Leucine, Tryptophan, Histidine, 
and Adenine (Clonetech Laboratories, CA, USA), indicating a stronger interaction.  
 
4.2.5	   Negative	  and	  positive	  control	  for	  Y2H	  
 
Plasmid constructs (pGAD/pGBD) lacking viral segment and salmon immune inserts were 
used as negative controls, while segment 8ORF2 together with 8ORF2 in pGAD and pGBD 
constructs were used as a positive control. J. Ramsell, Ph.D at NVI, established these controls. 
 
4.3. Co- Immunoprecipitaton (Co-IP) 
 
Co-immunoprecipitation studies were performed for further investigation of the novel protein-
protein interactions found during Y2H analysis. The expression vectors pDEST-Myc 
(Invitrogen, Carlsbad, USA) with ISAV segment inserts was provided by the NVI, while the 
expression vectors pDEST-GFP, (Invitrogen, Carlsbad, USA) for the IRFs were provided by 
the UIT. 
 
4.3.1	  	   Expression	  vectors	  for	  co-­‐Immune	  precipitation.	  
 
Primer design, amplification, purification cloning- and transformation procedures related to 
expression constructs used for co-IP studies are described in section 4.1. The vectors utilized 
for detection of protein-protein interactions are the pDEST-Myc vector with N-terminal Myc 
tag and the pDEST-GFP with C-terminal GFP tag.  
 
4.3.2	   Sequencing	  of	  the	  expression	  vectors	  for	  co-­‐immunoprecipitation	  
 
The sequence primer pDEST-GFP_fwd shown with nucleotide sequence in section 3.3 were sent to 
Macrogen, Korea for sequencing, along with the expression vectors in a concentration of 
100ng/µl, listed in Table 16.  
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Table 16: Immunoprecipitation expression vectors sent for sequencing 
Vector Interferon regulatory factor 
pDEST-GFP 3 
pDEST-GFP 7a 
pDEST-GFP 7b 
 
4.3.3	   Positive	  and	  negative	  controls	  for	  Co-­‐IP	  
 
The co-IP of the pDEST-Myc with ISAV segment 8ORF2 insert (pDEST-Myc 8ORF2) and 
the pDEST-GFP with ISAV segment 8ORF2 insert (pDEST-GFP 8ORF2), were used as 
positive controls as J. Ramsell, Ph.D at NVI, has established. The segment 8ORF2 is known 
to homodimerize (Manuscript in preparation). The negative IP controls of the pDEST-Myc 
8ORF2 from single transfectants, as well as the Co-IP of the (pDEST GFP STAT1 – pDEST 
Myc 8ORF2) was used. The last control mentioned were shown negative in Y2H screening 
analysis, see table 19.  
 
4.3.4	   Transfection	  of	  HEK	  293T	  cells	  for	  IP	  
 
Three days before the IP, the HEK 293T cells (ATTC, NY, USA) were plated so that the cells 
would be 90% confluent and at log phase the day of transfection. First, cells were washed in 
4ml phosphate buffered saline (PBS) and harvested in 2ml Trypsin EDTA buffer 200mg/L, 
(Lonza, Verviers, Belgium) until all cells were non-adherent. 10ml of DMEM with 2% L-
Glutamine antibiotics (200mM) (Lonza, Verviers, Belgium) and 10% Foetal Bovine Serum, 
FBS, (Invitrogen, Auckland, New Zealand) were added and centrifuged at 1200g for 
5minutes.  The supernatants were discarded and the cell pellet re-suspended in DMEM 
without antibiotics and distributed in aliquots of 2,5ml in 6-well plates (Corning incorporated. 
Corning, NY, USA.). 
 
Two days before the IP, the transfection of expression vectors pDEST-GFP and pDEST-Myc 
into 90% confluent HEK293 was performed, using Lipofectamine 2000, (Invitrogen). 
 
The Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) was used for transfection of 
pDEST-myc expression vectors encoding viral protein with N-terminal c-Myc tag. The 
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pDEST-GFP expression vector encoding salmon IRF protein with C-terminal GFP tag were 
diluted to 4µg (2µg for Co-IP) and mixed with 250 µl Opti-MEM (Invitrogen, Auckland, New 
Zealand.). 10 µl lipofectamin 2000 diluted in 250 µl Opti-MEM was incubated for 5 minutes 
and gently mixed with 250 µl plasmid solution, before it was incubated at room temperature 
for 20 minutes. The transfection mixes (~500 µl) were added to cells and incubated in a 
carbon dioxide incubator at 37°C for 48h. Transfected cells were inspected with a 
fluorescence microscope to look for GFP-fluorescent proteins.  
Lysates of HEK293T cells co-transfected with Myc- and GFP-tagged constructs were 
prepared by first placing the cells on ice. The medium was removed and the cells were 
washed very gently twice in ice cold PBS. The cells were then flushed off with ice cold PBS 
and transferred to a precooled tube. Cells were centrifuged at 1200g for 2min, the PBS was 
removed and the cell pellet lysed in 250ul NP-40 lysis buffer with protease inhibitors. 20µl of 
the sample was saved for analysis of protein expression in the total cell lysate. The rest of the 
sample was used in co-IP. The cell lysate were kept at 20°C until the time of the analysis. 
 
4.3.5	   Transfection	  control	  	  
 
Fluorescence microscopy was used as transfection control to detect the expression of the 
pDEST-GFP vectors. Fluorescence microscopy is a non-destructive analysis method of 
biological molecules that uses fluorescence for specific detection of single molecules. 
Fluorescence is the detected photon emission from a molecule that absorbe photons of a 
different wavelength, this phenomenon enables single molecule detection through 
fluorescence labelled biological material (Spring & Davidson, 2010). In this study the 
proteins encoded by pDEST-GFP expression vectors are labelled or tagged with the green 
fluorescence protein (GFP), and can be detected after transfection of HEK 293T-cells. GFP is 
susceptible for absorption of photons of 395nm and emission of green fluorescence at 507nm 
(Crameri, et al., 1996). Emission was detected in a LEICA DM IL Fluorescence microscope 
and photos of the transfection controls were taken using a Nikon DSMS digital sight camera. 
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4.3.6	   Antibody	  binding	  to	  Dynabeads	  
 
For immunoprecipitation, the rabbit anti-GFP antibody (Invitrogen), in a dilution of 1:2000, 
was bound to Dynabeads (Invitrogen Dynal As, Oslo, Norway.) First, Dynabeads were 
resuspended by pipetting and 15µl beads per sample were transferred to a tube. The tube with 
beads was placed on a magnet and the supernatant discarded. 2ug of αGFP Antibody were 
dissolved in 200µl PBS with 0.01% Tween and added to the beads. The beads-Ab complex 
was incubated by rotation for 1h at 4°C. The tube was placed on magnet and the supernatant 
removed. The tube was removed from the magnet and the beads-Ab complex resuspended in 
200µl PBS with 0.01% Tween.  
 
4.3.7	   Precipitation	  
 
The 230µl of total cell lysate was centrifuged for 10 min at 12 000 rpm at 4°C. The cleared 
lysate was transferred to a new tube, and kept on ice.  
The tube with the beads-Ab complex was placed on the magnet and as much as possible of the 
supernatant was removed. The cleared lysate was added to the beads-Ab complex and 
incubated through rotation for 10minutes at RT to allow the antigen (Ag) to bind the 
Dynabead-Ab complex (1hour or more for low affinity Ab). 
The tube was placed on a magnet and the supernatant was transferred to a new tube for further 
analysis if desired. The Dynabead-Ab-Ag complex was washed three times in 200ul of the 
non-denaturation NP40 lysis buffer and the supernatant re-suspended on magnet by gentle 
pipetting. Finally the dynabeads-Ab-AG complex was re-suspended in 100ul NP40 lysis 
buffer. To avoid co-elution of proteins bound to the tube wall, the bead suspension was 
separated on magnet into a new tube.  
Each target protein was eluted from solid support by adding 40 µl of 3x SB + 100mM DTT, 
3xSB with 100mM DTT was also added the total lysates. Both IP and total lysate samples 
were boiled for 5 min and quickly centrifuged to collect the sample at the bottom of the tube. 
4. Methods 
 52 
The samples were kept on ice before loading 20µl of them on the SDS-PAGE and letting the 
gel run at 100V for 15 minutes followed by 175V for 1hour. 
4.3.8	   Negative	  and	  positive	  control	  for	  co-­‐IP	  
 
Two negative controls were used in IP. The first is a single precipitation with 8ORF2 Myc. 
The second more strict negative control was STAT1, which was shown negative in Y2H, and 
used in co-IP as pDEST STAT1 GFP with the interacting target for positive control ISAV 
8ORF2 Myc (pDEST STAT1 GFP - 8ORF2 Myc). The positive control was the pDEST 
8ORF2 Myc - pDEST 8ORF2 GFP interaction found and established in co-IP by J. Ramsell, 
Ph.D at NVI. 
 
4.3.9	   Western	  Blotting	  for	  Co-­‐IP	  
 
The method of western blotting for Co-IP was performed as for Western Blotting for Y2H, 
see section 4.2.3 for a detailed description. Exceptions from that procedure described in 
regard the procedure after antibody hybridisation, which is specific for the Co-IP. This is 
described below. 
1. The incorporated c-terminal green fluorescence (GFP) and c-terminal Myc tag for 
pDEST-GFP and pDEST-Myc respectively, were detected with primary Rabbit anti-GFP 
Antibody diluted 1:2000 (Invitrogen. Eugene, Oregon, USA.), and Mouse anti-c-Myc 
Antibody, diluted 1:5000 (Invitrogen. Eugene, Oregon, USA.), for 1hour. 
2. The blot membrane was washed in PBS 0.1% Tween for 2x 15minutes at 200rpm by 
shake incubation. Secondary antibodies Goat anti Rabbit –HRP diluted 1:2000 
(Invitrogen. Eugene, Oregon, USA.), and secondary Goat anti Mouse –HRP diluted 
1:4000 (Invitrogen. Eugene, Oregon, USA.) were applied for pDEST-GFP and pDEST-
Myc respectively. The incubation mixture of secondary antibody´s included 1:10 000 
dilution of Precision protein Strep Tactin-HRP conjugate (BioRad, Hercules, CA, USA), 
for visualisation of the precision plus protein ladders. 
3. The blot membrane was washed in PBS 0,1 tween 20 for 2x 15minutes at 200rpm by 
shake incubation at room temperature.  
4. The following steps with activation of the HRP enzyme and blotted protein visualisation 
by chemi luminescence are the same as described in section 4.2.3. 
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4.4 Bioinformatics 
	  
4.4.1	   Comparison	  of	  Y2H	  and	  Co-­‐IP	  vectors	  with	  genes	  from	  GenBank	  
 
Local BLAST and the nucleotide search algorithm BLASTn were used from (CLC 
Workbench, Aarhus, Denmark.). DNA query was searched for in the GenBank nucleotide 
database with default settings, the sequence of the vector inserts was translated to verify that 
the sequences were in frame (without stop codons).  
 
4.4.2	   Coiled-­‐coil	  prediction.	  
The coiled-coil prediction was performed with coiled-coil prediction software programs 
available on internet; Paircoil (Berger, et al., 1995), and Multicoil (Wolf, et al., 1997). 
 
4.4.3 Alignment	  of	  IRF3	  from	  Human	  and	  Atlantic	  salmon	  
 
The human IRF3 is activated by phosphorylation first after viral infection. For prediction of a 
putative similar activation mechanism of the Atlantic salmon IRF3, a protein alignment was 
performed to look for evolutionary conservation of coiled-coil motifs found in human IRF3 
(Qin, et al., 2003). This would suggest a similar regulation of the Atlantic salmon IRF3.
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Chapter 5. Results 
 
It has previously been shown that ISAV segments 7ORF1 and 8ORF2 proteins exert IFN 
antagonistic activity (GarcÌa-Rosado, et al., 2008). To investigate where in the Atlantic 
salmon immune system the ISAV viral segments interact, we have screened for protein-
protein interactions using the yeast-two-hybrid technology and further studied our findings 
with immunoprecipitation. The results of this study are here presented. 
 
5.1 Screening for protein-protein interactions using Yeast-Two-
Hybrid (Y2H) 
 
Genes potentially involved in the mechanisms for IFN antagonistic activity during ISAV 
infection were chosen as candidates for a protein- protein interaction screening using the Y2H 
technology. Genes central in the interferon type I signalling cascade, such as TLR8, TLR9, 
IRF3, IRF7, MyD88, TRIF and STAT1 were inserted in pGBD vectors. The ISAV segments 
were inserted in pGAD vectors. These expression vectors were provided by Professor Jorunn 
Jørgensen, UIT. Dr. Jon Ramsell, NVI, cloned the ISAV genes into the pGAD-vectors.  
 
5.1.1	   	  Identifying	  the	  vector	  inserts	  used	  in	  Y2H	  experiments	  
 
All the inserts in expression vectors were sequenced to verify sequence identity – which is 
crucial for providing reliable results.  
 
Y2H vector inserts were compared with genes from GenBank using a BLASTn search. The 
results showed that all expression vector inserts sequences matched the wanted nucleotides 
for gene expressions, shown in Table 17. This made them reliable for use in the Y2H protein-
protein interaction screening analysis.  
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Table 17: Alignment of sequenced pGAD and pGBK vector nucleotides searched against 
GenBank  
Query sequence Hit description 
E-
value 
Bit 
score 
Query 
start 
Quey 
end Identity 
Gap
s 
pGAD_7ORF2_fwd 
DQ785262  
(ISAV 4, segment 7) 0 831 222 640 419 0 
pGAD_7ORF1_fwd 
DQ785262  
(ISAV 4, segment 7) 0 1 560 164 950 787 0 
pGAD_s4_fwd 
DQ785220  
(ISAV 4, segment 4) 0 1 564 162 950 789 0 
pGAD_8ORF1_fwd 
DQ785276  
(ISAV 4, segment 8) 0 1 172 164 754 591 0 
pGBK_8ORF1_rev 
DQ785276 
(ISAV 4, segment 8) 0 1 172 827 237 591 0 
pGAD_S3_fwd 
DQ785206  
(ISAV 4, segment 3)  0 1 562 163 950 788 0 
pGAD_8ORF2_fwd 
DQ785276  
(ISAV 4, segment 8) 0 1 441 158 888 730 0 
pGBD_IRF7A_rev 
EU153263  
(Salmo salar IRF7A)   0 1 630 100 950 842 0 
pGBD_STAT1_rev 
GQ325309  
(Salmo salar STAT1)   0 1 388 950 243 706 0 
pGBD_TLR9_rev 
NM_001123653  
(Salmo salar TLR-9)  0 1 132 810 240 571 0 
pGBK_IRF3_rev 
FJ517643  
(Salmo salar IRF3) 0 1 628 98 950 949 0 
 
Expression vectors for use in Y2H were identified with E-values at zero, this indicates that the 
probability of finding a better match is zero. We controlled that these sequences were in a 
proper reading frame for translation using CLC Main Workbench. 
 
The pGBD and pGAD-vectors were transformed into PJ69-2A and Y187 yeast cells 
respectively, using Frozen-EZ yeast transformation II (Zymo research). These PJ69-2A and 
Y187 cells were grown on selective media lacking Trypthophan and Leucine respectively. 
The molecular size of the vector inserts from the ISAV-expressed proteins were analysed on 
Western blot, illustrated in figure 11a and 11b. 
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5.1.2	   Western	  blot	  for	  Y2H	  
The molecular size of the expression vectors used in Y2H were visualized by Western 
blotting, results are shown in figure 11a and 11b. This was enabled using the HA tag of 
pGAD, and the Myc tag of pGBD. Figure 11a shows the expressed pGBD-vectors, while 
figure 11b shows the expressed pGAD-vectors.  
 
 
Figure 11a. SDS PAGE of expressed ISAV segments in pGBD vectors transformed into Saccharomyces 
cerevisiae PJ69-2A yeast cell strain (Clonetech, Laboratories, Mountain View, CA, USA.). 
 
ISAV segments inserts in pGBD with Myc-tag were blotted with rabbit-anti hemagglutinin 
(αHA) 1:500 (Invitrogen, Invitrogen. Eugene, Oregon, USA.), followed by goat-anti-rabbit –
HRP 1:2000 (Invitrogen, Invitrogen. Eugene, Oregon, USA.).  
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Figure 11b.  SDS PAGE of expressed ISAV segments in pGAD vectors transformed into Saccharomyces 
cerevisiae Y187 yeast cell strain (Clonetech, Laboratories, Mountain View, CA, USA.). 
 
ISAV segment inserts in pGAD with a translating HA tag were blotted with mouse-anti-Myc 
1:5000 (Invitrogen, Eugene, Oregon, USA.), followed by goat-anti-mouse–HRP 1:4000 
(Invitrogen, Eugene, Oregon, USA.). The molecular size of the ISAV proteins compared to 
the predicted size (Appendix 1.), are shown in Table 18. 
 
Table 18: Corresponding molecular size (kDA) of ISAV segment expressed proteins for 
Yeast-two-hybrid analysis 
ISAV segment 1 2 3 4 5 6 7ORF1 7ORF2 8ORF1 8ORF2 
pGBK (kDa) 78  67 66   35 17 22 25/37 
pGAD (kDa)  77 67 65   35 17 22 25/37 
The expressed ISAV proteins that corresponded to the predicted molecular size (Appendix 1) are marked in 
green. Non-corresponding ISAV-segment expressed proteins are marked in red. 
 
The molecular size of “empty vectors” is 23kDa for both pGAD and pGBD, shown in figure 
11a and 11b. The molecular size of these vectors lacking inserts is withdrawn from the Y2H 
vectors with an insert, and comparison to the predicted molecular weight (Appendix 1). The 
ISAV segment 2 pGBD was not expressed because the sequencing of the insert showed 
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insufficient results, for documentation see Appendix 2. To get all ISAV segments in both 
Y2H-vectors the initial steps with primer design, PCR and cloning of segment 5 and 6 into the 
pDEST-vector were performed, but due to lack of time the samples with non-corresponding 
molecular size were not studied further. 
 
5.1.3	   Yeast-­‐Two-­‐Hybrid	  mating	  
 
Proteins expressed from pGBD and pGAD-vectors that interact during mating enabled us to 
grow colonies on selective media. The stringency of the protein-protein interaction was 
measured in selective media, and to confirm that mating has occurred, double dropout 
medium (DD) was used. Triple dropout medium (TDO) indicates a protein-protein 
interaction, while quadruple dropout medium (QDO) indicates an even stronger protein-
protein interaction. The first aim of this study was to identify possible protein-protein 
interactions between ISAV proteins. Only the interaction between 8ORF2 together with 
8ORF2 was found. This interaction was used as positive control in further studies where the 
ISAV proteins were mated with proteins from the Atlantic salmon innate immunity. Results 
are shown in Table 19. 
 
Table 19: Scoring of protein interactions between the innate immune system of the 
Atlantic salmon and the ISAV in the Y2H-model  
pGBK/pGAD Empty Myd88 IRF3 IRF7a STAT1 TLR8 TLR9 TriF 8ORF2 
Empty - - - - - - - - - 
Seg.1 - - - - ++ - - ++ - 
Seg.2 - - - - ++ - - ++ - 
Seg.3 - - +++ - - - - ++ - 
Seg.4 - - - - ++ - ++ ++ - 
Seg.5 - - - - - - - - - 
Seg.6 - - - - - - - - - 
7ORF1 - ++ ++ ++ ++ - - - - 
7ORF2 - - - - - - - - - 
8ORF1 - - - - - - - - - 
8ORF2 - - +++ +++ - ++ - - +++ 
Growth was scored after 6 days, when the positive control 8ORF2 with 8ORF2 showed massive growth on 
quadruple dropout medium (QDO) lacking Leucine, Tryptophan, Histidine, and Adenine. +++ massive growth 
on QDO (a strong interaction); ++ massive growth on triple dropout medium (TDO) lacking Leucine, 
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Tryptophan, and Histidine (indicates a weaker interaction). Empty plasmid constructs with vectors lacking viral 
proteins or salmon immune clone were used as negative controls. 
 
The protein-protein interactions between IRF3, IRF7A and ISAV segment 8 ORF2 are shown 
in figure 12. 
 
Figure 12. Growth of mated Y2H on selective media indicating the stringency of the protein-protein interactions. 
Plasmid constructs with vectors lacking viral proteins or salmon immune clone (3,5,6,7,8) were used as negative 
controls, while ISAV segment 8ORF2pGBD- ISAV segment 8ORF2pGAD (4) served as positive control.  
 
The IRF3/IRF7a interaction with ISAV 8ORF2 was measured according to the stringency of 
growth on selective media; as these grew under all types of stringency, this indicates a strong 
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protein-protein interaction. The most interesting protein-protein interactions found during 
Y2H screening was investigated further using co-immunoprecipitation for verification of the 
findings. 
 
5.2 Verification of protein-protein interactions using co-
immunoprecipitation 
 
The detected protein-protein interactions between (IRF3 - ISAV 8ORF2) and (IRF7a – ISAV 
8ORF2), were chosen for further investigation using co-immunoprecipitation (Co-IP). Both 
are candidates to be involved the IFN antagonistic activity of ISAV. In this co-IP study, we 
used pDEST-Myc and pDEST-GFP as expression vectors. We also analysed an additional 
IRF7b insert in p-DEST-GFP, but decided to exclude it from further analysis. This because 
the analysis showed that the pDEST-IRF7a insert was equal to the IRF7a insert used in Y2H, 
which made it suitable for further study. 
 
5.2.1	   Identification	   of	   the	   pDEST	   –GFP	   vector	   sequence	   used	   in	   co-­‐
immunoprecipitation	  
 
The UIT provided the pDEST-GFP expression vector constructs with IRFs inserted. As 
illustrated in figure 13 and 14, these inserts were sequenced and matched against GenBank 
using BLASTn. The positive control vectors (pDEST 8ORF2-GFP - pDEST 8ORF2-Myc) 
were identified by Dr. J.Ramsell (data not shown).  
 
 
Figure 13: Local Blastn visualisation of IRF3 pDEST-GFP vector sequence as query and the best match of the 
local database with accession number FJ517643 (IRF3). 
 
As shown in figure 13, IRF3 pDEST-GFP is identical (E-value=0) to the Atlantic Salmon 
IRF3 corresponding sequence from the GenBank. The result presented in figure 14 shows that 
IRF7a is equal to the Atlantic Salmon IRF7a sequence from the GenBank. 
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Figure 14: Local Blastn visualisation of the IRF7a pDEST-GFP vector sequence as query and the best match of 
the local database with accession number EU153263 (IRF7a). 
 
The verification of the insert sequences of the expression vectors used in IP are summarised in 
Table 20. The results show that the insert sequences of the expression vector matched the 
wanted nucleotides for gene expressions.  
 
Table 20: Alignment of sequenced pDEST-GFP vector sequences  
Query sequence Description 
E-
value 
Bit -
score 
Query 
start 
Query 
end Identity Gaps 
IRF7A-GFP_FWD EU153263(IRF7A) 0 1 629,99 100 950 842 0 
IRF3-GFP_FWD FJ517643.1(IRF3) 0 1 628,01 98 950 849 5 
 
After validation of the vector inserts for the IP samples the pDEST-Myc and pDEST-GFP 
vectors were single-transfected or co-transfected into HEK 293T cells. The transfection step 
was also validated through transfection controls. 
 
5.2.2	   Transfection	  control	  by	  detection	  of	  fluorescence	  from	  translated	  pDEST-­‐GFP	  
vectors	  
 
For the transfection control we used the pDEST-GFP vectors expression of their c-terminal 
GFP tag, as visualized by fluorescence microscopy. The transfection efficiency is measured in 
the amount of emitted fluorescence. Figure 16 shows the transfection efficiency of the 
pDEST-GFP vector with IRF3 and IRF7a inserts as found in this study. 
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Figure 16. Transfection efficiency of single-transfected and co-transfected HEK293T cells visualised with 
fluorescence microscopy. a) ISAV 8ORF2 pDEST Myc - IRF3 pDEST GFP, b) ISAV 8ORF2 pDEST Myc - 
IRF7a pDEST GFP, c) ISAV 8ORF2 pDEST Myc - IRF7b pDEST GFP d) Positive transfection and 
immunoprecipitation control (ISAV 8ORF2 pDEST GFP - ISAV 8ORF2 pDEST Myc, e) Positive transfection 
and negative immunoprecipitation control STAT1 pDEST GFP - ISAV 8ORF2 pDEST-Myc, f) Negative 
transfection and precipitation control ISAV 8ORF2 pDEST Myc. a to e are co-transfections while f is a single-
transfection. 
 
5.2.3	   Detection	  of	  Co-­‐precipitated	  proteins	  on	  Western	  Blot	  
Western Blot was used for detection of co-IP with rabbit-anti-GFP antibody 1:2000 
(Invitrogen, Eugene, Oregon, USA.). The ISAV proteins Myc tag and the IRF proteins GFP 
tag enabled the detection with αMyc antibody (Figure 17a) and αGFP antibody (Figure 17b), 
respectively. 
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Figure 17a Detection of interactions between the analysed proteins using Western Blot of co-IP with αGFP 
precipitation incubated with αMyc antibodies, visualizing the Myc tag of precipitated proteins. 
 
Immunoprecipitations were performed with αGFP pull-down and the incubation with 
primarily and secondary αMyc-antibodies was used for detection of Myc tagged proteins. The 
results for the positive control (ISAV 8ORF2 GFP – ISAV 8ORF2 Myc) showed a strong 
ISAV 8ORF2 Myc band at 37kDa. The estimated size of 27kDa for ISAV 8ORF2 matches 
well with its predicted molecular size (Appendix 1), as the size of the Myc tag itself is 10kDa. 
The results of the negative controls (STAT1 GFP- ISAV 8ORF2 Myc) and (ISAV 8ORF2 
Myc) were both negative for ISAV 8ORF2 Myc. The results for the interactions found in 
Y2H, (IRF3 GFP – ISAV 8ORF2) and (IRF7a GFP – ISAV 8ORF2), showed weak bands for 
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ISAV 8ORF2 Myc. The antibody contamination bands at 50kDa and 30kDa showed the 
heavy and light chain of the precipitation antibody.  
 
 
Figure 17b Western Blot of co-IP precipitated with αGFP now incubated with αGFP (in addition to the earlier 
αMyc incubation in 17a). Here visualizing the GFP tag of precipitated proteins, to see that precipitation 
occurred. 
 
To validate that co-precipitation had occurred the immunoprecipitations were performed with 
αGFP pull-down. The incubation was performed with primary and secondary αGFP, as the 
incubation with αGFP antibodies detects GFP tagged proteins. The molecular size of the GFP 
tag itself is 30kDa. The results showed that the negative control (STAT1 GFP- ISAV 8ORF2) 
had a STAT1 GFP band at the size of 115kDa, estimated to 85kDa. The other negative control 
(ISAV 8ORF2) had no band as predicted. The result of the positive control (ISAV 8ORF2 
GFP – ISAV 8ORF2 Myc), showed an ISAV 8ORF2 GFP band at 58kDa, estimated to 
28kDa. The results for the interactions found in Y2H are presented as follows: The (IRF3 
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GFP – ISAV 8ORF2) had an IRF3 GFP band at 80kDa, estimated to 50kDa. The (IRF7a GFP 
– ISAV 8ORF2) had an IRF7a GFP band at 75kDa, estimated to 45kDa. To validate the 
estimated molecular sizes, we compared them to their predicted molecular sizes (Appendix 1). 
The results showed that the proteins were of suitable size.  
 
The findings of the Y2H screening and the further investigation by co-IP are gathered in a 
schematic map of interactions between key proteins of the IFN system and proteins of the 
ISAV, shown in figure 18. 
 
 
Figure 18: Protein interactions found using yeast-two-hybrid are marked in stippled lines and protein 
interactions verified with immunoprecipitation are marked in bold lines between the protein symbols. ISAV viral 
proteins (VP) are marked red, while proteins expressed from Atlantic salmon innate immunity are marked blue. 
 
5.3 Functional studies 
5.3.1	   Coiled-­‐coil	  prediction	  
For the prediction of possible coiled-coil motifs for the Atlantic salmon IRF3 and IRF7a we 
performed online algorithm programs, Multicoil and Paircoil (for further reference, see 
section 3.7). The results showed no coiled-coil motifs for any of the IRFs. 
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5.3.2	   Conserved	  regions	  within	  the	  IRF	  genes	  
To investigate whether the IRF proteins of ISAV and human IRF3 contained conserved 
regions, hypothesized to be important for function, the homology between human- and ISAV- 
IRF3 and IRF7a was analysed. The results are shown in figure 19. 
 
 
gi|38492947|pdb|1QWT|B Chain B, Auto-Inhibitory Interferon Regulation Factor-3 (Irf3) Transactivation Domain 
gi|219972763|gb|FJ517643.1| Salmo salar interferon regulatory factor 3 (IRF3) mRNA, complete cds 
gi|159792915|gb|EU153263.1| Salmo salar interferon regulatory factor 7 mRNA, complete cds 
 
  ----------------------SPSLDNPTPFPNLGPSENPLKRLLVPGEE-WEFEVTAFYRGRQVFQQTISCPEGLRLV 
1 VMEDAVGGAVLP-PQPVYPMDGP--VGGAHEQQVVEQFTNELSRTMVGENFKTHFRVSVYYRGLKMLEQLVENEAGFRLV 
1 PP-------------------------VLIQQPYAQVNPDALLNLPATRSSLWDLEITISYRGSEMLKTQVSGPR-VQLH 
  
  -GSEVGDRTLPGWP----VTLPDPGMSLTDRGVMSYVRHVLSCLGGGLALWRAGQWLWAQRLGHCHTYWAVSEELLPNSG 
  YRPELTQPLLDPDSGLNLVSLPSPP-PVRDETQAKLTQDILALLGEGLEVGASGPIIYGLRKGGIKAFWSLDK--FDKSR 
  YQCNALEPNTQP------LCFPSTD-GLPDLKQIEYTNCILRSVQRGLLLEVQNTGIYGYRQDKCHVFSSTSN---PREA 
 
  HGPD-GEVPKDKEGGVFDLGPFIVDLITFTEGSGRS-PRYALWFCVGESWPQ--DQPWTKRLVMVKVVPTCLRALVEMAR 
  RPQAVSKFPE----PLYQAKDFYGGLLKFMDSHRGECPPFSLFFCLGEKWPDPDNRPWEKKLVMVEVVLTALELLKSIAV 
  HPEP-RKMPQNEMVQLLNFQQYENELIAFKENRRGS-PDYTIHMCFGEKFPD--GKPPEKKLIVVKVVPLICRYFHEVAQ 
  
  VGGASSLENT-VDLHISNSHPLSLTSDQYKAYLQDLVEGMDFQGPGES 255 
  EGGASSLQS--VELQLSLQESLQEVMDLC------------------- 481 
  EEGASSLQND-ISLQISHHNSLMELINATWPDGPQHTMGQYF------ 415 
 
 
Figure 19. A protein-BLAST (BLASTp ) alignment with human IRF3 as query aligned with IRF3, IRF7a, 
performed at PubMed. 
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Chapter 6. Discussion 
 
The type I interferon system is a key player in the host cells inhibition of viral replication 
during an infection. The ISAV segment 8ORF2 and 7ORF1 have been shown to exert 
interferon antagonistic activity in Atlantic salmon (GarcÌa-Rosado, et al., 2008). Knowledge 
gained by collaborative researchers at UIT and NVI served as a starting point of the practical 
work in this project. They have previously characterized proteins from the IFN system in 
Atlantic salmon as well as proteins from the ISAV. In this study, we found several protein-
protein interactions between virus and host, these findings are here discussed in the light of 
known mechanisms in other Orthomyxoviruses with IFN antagonistic genes.  
 
6.1 Screening for protein-protein interactions with Y2H 
 
The protein interactions found by the Y2H screening were divided into strong interactions and 
weaker interactions. Strongly interacting proteins were indicated by growth on the most 
selective QDO medium, we found that (IRF3 - ISAV 8ORF2) and (IRF7a - ISAV 8ORF2) 
interacted strongly. This analysis was confirmed by the positive control (ISAV 8ORF2 - 
ISAV 8ORF2), which showed massive growth on QDO media, see figure 12. These two 
strong interactions of (ISAV 8ORF2 - IRF3) and (ISAV 8ORF2 - IRF7a) are both involved in 
the IFN system and are therefore particular interesting for IFN antagonistic activity. This will 
be discussed further in section 6.2 and 6.3.  
 
Growth on the TDO medium indicated a weaker protein-protein interaction, which was found 
for the pathogen recognition receptors, TLR 8 and TLR 9, both of these TLRs showed 
interactions with the ISAV, (TLR8 - 8ORF2) and (TLR9 - ISAV segment 4). However, TLR9 
is referred to as able to recognize DNA virus and TLR8 to recognizes ssRNA virus, making 
the TLR8 interaction with 8ORF2 more likely because ISAV is an ssRNA virus. The finding 
of TLR8 interacting with 8ORF2 indicates an IFN induction through the MyD88 signalling 
pathway. Another interaction of the MyD88 pathway was the interaction between (ISAV 
6. Discussion 
 68 
7ORF1 - MyD88), suggesting that this might be the protein-protein interaction that inhibits 
the IFN production and therefore also inhibit the antiviral state upon viral infection (figure 3.). 
Dr. J.Ramsell, NVI, earlier found the interaction of MyD88 with ISAV segment 7ORF1. 
Nonetheless, MyD88 does not necessarily have a key role in the down regulation of IFN, as 
the MyD88 adaptor primarily induces an interleukin expression (Leichtle, et al., 2009 ). 
However, the interactions of TRIF with ISAV segments 1,2,3 and 4 indicate an inhibition of 
the IFN through the other IFN pathway with TRIF as adaptor molecule (figure 4.). The TRIF 
is strictly activated by dsRNA virus recognition of TLR3, now TLR 3 were not investigated in 
this study but have been found for the recognition of ssRNA Influenza A virus (Le Goffic, et 
al., 2006). A very interesting interaction in mammals involved in the IFN antagonistic activity 
is the cytoplasmic interaction between viral ssRNA and IRF7a (Haller, et al., 2006). Protein-
protein interaction data found in this study supports the data from Haller et al., 2006, where 
the interaction of (IRF7a - ISAV 7ORF1) was found. The ISAV 7ORF1 has been located in 
the cytoplasm and is hypothesized as an IFN antagonist (GarcÌa-Rosado, et al., 2008), 
indicating an actual antagonistic interaction between the ISAV 7ORF1 and the innate 
immunity of Atlantic salmon. Due to lack of time, the interactions of (IRF7a - ISAV 7ORF1) 
were not verified with co-IP in this study.  
 
The non-interacting ISAV proteins 7ORF2 and 8ORF1 both validated with visible protein 
expressions in Western blot (figure 11a and 11b) suggest that neither the ISAV 7ORF2, nor 
the ISAV 8ORF1 proteins are responsible for inhibiting the antiviral state. This might be 
explained by their maintaining functions of the virus (O'Neill, et al., 1998), and (Falk, et al., 
2004). 
 
Despite the earlier findings, we failed to validate some of the protein expressions from Y2H 
vectors; the ISAV segment 2 in pGBD, ISAV segment 1 in pGAD, and ISAV segment 5 and 
6 in both pGAD and pGBD (figure 11a and 11b). The results regarding ISAV segment 5 and 
6 can be explained by the fact that these vector inserts encodes trans membrane proteins, 
fusion and hemagglutinase-esterase proteins respectively. Trans membrane proteins have two 
hydrophilic ends and a lipophilic core expressed over the plasma membrane of the cell, and 
their expressed protein is therefore hard to analyse (Phizicky & Fields, 1995). The ISAV 
segment 2 had a insufficient vector insert (Appendix 2) resulting in absent protein expression 
while ISAV segment 1 in the pGAD vector showed several interactions during Y2H 
screening, suggesting that a moderate amount of the protein was expressed. 
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6.2 Verification of protein-protein interaction using co-   
immunoprecipitation (co-IP) 
 
The co-immunoprecipitation gave results difficult to interpret even though the co-
precipitation controls showed the expected results for all co-precipitated samples (figure 17b). 
We found a 37kDa band of ISAV 8ORF2 Myc (figure 17a), indicating an interactions 
between (IRF3 GFP – ISAV 8ORF2 Myc) and between (IRF7a GFP – ISAV 8ORF2 Myc), 
but compared to the positive control, the detection of the interactions was very weak, see 
figure 17a. This suggests that the interactions between (IRF3 GFP – ISAV 8ORF2 Myc) and 
(IRF7a GFP – ISAV 8ORF2) were doubtful and that the interactions of them found in Y2H 
was not detected in co-IP since co-IP analysis is a high confidence assay, which display that 
Y2H is known to provide false positives (Deane, et al., 2002). However, the IRF3 GFP and 
IRF7a GFP inserts transfected into HEK293T cells expressed their proteins in moderate 
amounts. They were both detected with a low amount of fluorophors from their GFP tags 
(figure16), indicating low transfection efficiency. Even though a 2x and a 5x amount of 
transfected cells were used for IRF3 GFP and IRF7a GFP, respectively, they were not close of 
the flourophore intensity of the positive control ISAV 8ORF2 GFP. This indicates that the 
interaction between (IRF3 GFP – ISAV 8ORF2), and (IRF7a GFP – ISAV 8ORF2) is an 
actual interaction but with a low transfection efficiency. However, the weak interaction may 
also depend on the fact that the IRF3 is more accessible for interactions after viral infection, 
causing a configuration switch of the IRFs (Dragan, et al., 2007). This is further discussed in 
section 6.3. 
 
To validate the co-IP, all co-transfected samples had an incorporated GFP tag in a vector 
insert and a Myc tag in the other vector insert. After expression in the host these protein tags 
were detected with anti GFP antibody (figure 17b), and anti Myc antibody (figure 17a). The 
interacting proteins were proven by detection of both of their protein GFP and Myc tags. In 
this study, the co-precipitated negative control (STAT1 GFP – ISAV 8ORF2) showed the co-
precipitated GFP protein, while the single-transfected negative control (ISAV 8ORF2 Myc) 
showed no GFP protein as expected. These results of the negative controls show that no 
interaction of co-precipitated 8ORF2 Myc was made with the GFP tag alone, and that no false 
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negatives were produced by single-precipitation of ISAV 8ORF2 Myc proteins, therefore our 
findings are reliable and not a product of non-specific bindings, which are known as a 
common interference in co-IP (Phizicky & Fields., 1995). Another aspect of producing false 
positive results is the possibility to detect interactions between proteins that are never present 
in the same cell. As the mechanisms of the ISAV are not yet fully understood, it is yet to 
prove, whether the protein interaction found in this study in fact are present in the same cell.  
 
6.3 Protein-protein interactions and their putative function in the 
immune system. 
 
ISAV 8ORF2 has a predicted coiled-coil motif (GarcÌa-Rosado, et al., 2008) and it is stated 
that protein-protein interactions are mediated by coiled-coil motifs (Huang, et al., 2005). This 
suggest that the interactions between the proteins of the positive control used in Y2H and co-
IP (ISAV 8ORF2 – ISAV 8ORF2), mediate dimerization of their proteins through their coiled 
coil motifs. This indicates that the IRF3/IRF7a interaction with ISAV 8ORF2 can be a result 
of coiled-coil mediated interaction between the residues. Nonetheless, IRF3 and IRF7a were 
not detected with coiled-coil motifs using the coiled-coil prediction programs Paircoil and 
Multicoil. However, the IRF3/IRF7a were found to interact with ISAV 8ORF2, which has 
been located to the nucleus (GarcÌa-Rosado, et al., 2008). This suggests a likely IFN 
antagonistic protein-protein interaction in the nucleus of ISAV 8ORF2 and IRF3, as IRF3 is 
located to the cell nucleus upon viral infection (figure3.) and a inducer of IFN that provides 
the antiviral state in the host cell (Robertsen, 2006). The result from the coiled-coil prediction 
studies in this thesis suggests that the interaction between ISAV 8ORF2 and IRF3 is not a 
coiled-coil mediated interaction. However, IRF3 in mammals is thought to be activated first 
upon virus infection by phosphorylation’s in the C-terminal, that increases the negative charge 
of IRF3 that results in the IRF-3 dimerization (Dragan, et al., 2007). This suggests that 
Atlantic salmon IRF3 and IRF7a make the folding of coiled–coil first post virus infection. 
Moreover, the IRF3 and IRF7a transfection with ISAV 8ORF2 is performed with non-
infected cells, suggesting a low, if any, activation of the essential coiled coil motif of IRF3 to 
induce IFN (Dragan, et al., 2007). Furthermore the IRF3 and the IRF7a are suggested to be 
activated the same way (Iwamura, 2001). Those findings are shown to be likely in this thesis, 
where the conserved regions important for function are shown to be very similar for IRF3 and 
IRF7a (figure 19). Moreover, the evolutionary-conserved regions for human IRF3 show great 
similarity to the IRF3 and IRF7a proteins from Atlantic salmon (figure19), indicating that the 
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function of human IRF3 equals the Atlantic salmon IRFs. The phosphorylation activation of 
IRF3 has been mimicked by phosphomimetic Asp substitution of Ser/Thr mutagenesis in vitro 
in Human, demonstrating the full coiled-coil motif of IRF3 first after activation (Dragan, et 
al., 2007). If the functions of Human IRF3 and Atlantic salmon IRF3 are the same, the 
assumption can be made that the interaction between the IRFs and ISAV 8ORF2 proteins in 
this study would have been stronger if both of the IRF were investigated with ISAV 
stimulated cells.  
 
Moreover, Orthomyxoviruses have evolved from the same origin and Influenza A, 
Thogovirus, and ISAV all have strategies to suppress the induction of type I IFNs. Thus 
indicating that the mechanisms to suppress the IFN induction could be similar among 
Orthomyxoviruses. It has earlier been shown that not only one gene is responsible for IFN 
antagonism of ISAV, as common for Thogovirus and Influenza virus (Jennings, et al., 2005), 
(Talon, et al., 2000), but both ISAV 7ORF1 and 8ORF2 genes suppress IFN independent of 
each other (GarcÌa-Rosado, et al., 2008). The NS1 of Influenza A is suggested to suppress 
IFN through the IRF3 inhibition in the cytoplasm (Talon, et al., 2000), a feature that is shared 
with the ISAV segment 7ORF1. This segment is also located in the cytoplasm with 
hypothesized IFN antagonistic activity, suggesting that the ISAV 7ORF1 interaction with 
IRF3/IRF7a in the cytoplasm is involved in the ISAV antagonistic activity through 
suppression of the IFN positive feedback (Haller, et al., 2006). However, the ISAV 7ORF1 
interaction with IRF3/IRF7a could not be analysed with co-IP due to the lack of time, and 
therefore would have to be verified in further studies. The hypothesized IFN suppression of 
ISAV 8ORF2 localized in the nucleus (GarcÌa-Rosado, et al., 2008) has similar characteristics 
as the IFN antagonistic ML protein of Thogovirus, inhibiting IFN transcription in the nucleus 
(Jennings, et al., 2005). Furthermore the ISAVs two IFN antagonistic proteins encoded by 
segment 7ORF1 and 8ORF2, are hypothesized to be independent of each other (GarcÌa-
Rosado, et al., 2008). This suggests that they do not interact with the same IRF in native form, 
but that ISAV 8ORF interacts with IRF3, as both are localized in the nucleus, and ISAV 
7ORF1 interacts with IRF7a, as both are localized in the cytoplasm. 
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6.4 Further aspects 
 
To get a better understanding of the protein-protein interactions of (ISAV 7ORF1 - IRF7a) 
and (ISAV 8ORF2 – IRF3), we need further studies for verification, in order to get a clearer 
picture of the mechanisms involved during IFN antagonism caused by ISAV. To enable a 
more distinct detection during co-IP studies we could use a huge amount of co-transfected 
host cells, or as a second opportunity to study viral activated IRFs. 
 
The mechanisms of the IFN system upon viral infection are not yet fully understood, and 
more research is needed to get one step closer to a fully understanding of the ISAV host 
mechanisms. Which in the end might be used in the development of more efficient prevention 
methods such as a vaccine against ISAV, or for other virus within the Orthomyxoviridae.    
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Appendix 1 Predicted molecular size of expressed pDEST inserts 
 
Predicted molecular size of expressed pDEST insert 
Insert Predicted 
(kDa) 
S1-PB2 79 
S2-PB1 80 
S3-NP 66-71/ 77 
S4-PA 65 
S5-F 50-53/ 45 
S6-HE 37/ 42-43 
S7O1 34 
S7O2 16 
S8O1 22-24 
S8O2 27/ 35 
IRF3 53 
IRF7a 48 
IRF7b  52 
STAT-1 87 
 
Predicted molecular size (kDa) performed by Expasy. 
 
Appendix 2 
 81 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 2 
 82 
 
Appendix 2 Sequnece of pGBD 2 expression vector for insert  
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